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Mammary stem cells (MaSC) are under stringent scrutiny these recent years, due in no 
small part to the fact that breast cancer is the most common cancer among females 
worldwide and that MaSC have been extensively studied as a system to delineate the 
pathogenesis and treatment of breast cancer. However, research on MaSC requires 
tissue biopsies which limit the quantity of samples available. Taking reference from 
other systems with epithelial cells’ lining, studies have document the presence of the of 
the stem cell in the luminal discharges due to the proximity of the stem cell niche to 
their luminal cavities. For example, mesenchymal progenitor cells have been isolated 
through the collection of human menstrual blood and urothelial stem cells have been 
derived from urine. Extrapolating these reports to a tissue of common lineage, they 
suggest the plausibility of mammary stem/ progenitor cells being shed into human 
breast milk (HBM) either by means of sloughing or active shedding into the lumen for 
yet unknown purposes during a time of intense cellular turnover. 
 
In my study, I hypothesised that stem cells are shed into the HBM and aimed to isolate 
them from HBM. Successful derivation of these cells from HBM may aid progress of 
research in mammary stem/ progenitor cells by providing a novel and non-invasive 
source. In addition to allowing a comprehensive understanding of the various 
components of HBM throughout the entire lactational period, this novel cell source may 
contribute to the reconstruction of the mammary tissues, and the unshedding of 
mechanisms behind the link between MaSC and breast cancer. 
 
HBM contains a mixed population of cells of haemopoietic, mesenchymal and neuro-
epithelial lineages. Further analysis of the adherent cultured cells reveals a 




heterogeneous population of cells with differential expression of cytokeratin (CK)5, 
CK14, CK18 and CK19. In addition, there was a small population of nestin-positive 
cells (16.0±2.6%), of which 53.1±4.2% and 55.2±2.85% co-stained with CK5 and CK 
19 respectively, and only 22.3±1.5% and 26.0±2.7% co-stained with the more mature 
epithelial markers, CK14 and CK18 respectively. This suggests a hierachical model of 
mammary cells within our culture system with the nestin+ cells being the putative 
MaSC followed by the intermediates of nestin+CK5+ and nestin+CK19+ cells, which 
are in turn more immature than the nestin+CK14+ and nestin+CK18+ cells. The 
terminally differentiated cells in our model would be the nestin-CK14+ and nestin-
CK18+ cells. 
 
In order to prospectively isolate putative MaSC for characterisation, two different 
approaches were undertaken. Firstly, flow cytometric sorting of side population (SP) 
cells revealed that 2% of cellular component of HBM were able to exclude Hoeschst 
33342 dye, which selects for primitive stem cell populations. HBM SP cells co-
expressed nestin but not the mature epithelial marker CK18. However, attempts to 
culture expand these putative MaSC in a wide range of in vitro conditions did not result 
in any mammary nor haemopoietic stem cells. Next, prospective isolation through 
selection of CD133 positive cells was done. Two percent of HBM were CD133-positive. 
These cells did not contain any haemopoietic activity, nor were attempts to expand 
them successful.   
 
The derivation of MaSC from HBM would have availed a non-invasive source of stem 
cells of relevance to the understanding of lactation biology, oncogenesis and 
regenerative medicine. While some markers of primitive cell types of hierarchical 
Summary 
   
xii 
importance were detected, there was no evidence of any cell types with self-renewal 
and multi-lineage differentiation capacity. This may in part be due to poorly defined 
growth conditions, or the absence of such cell types in HBM. 
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 Lactogenesis and Lactation 
1.1.1 Lactogenesis 
Lactogenesis is defined as the process by which the mammary gland develops the 
capacity to secrete milk (Neville 1999). It can be divided into phase I and II. Phase I 
occurs during mid-pregnancy with the initiation of secretory differentiation with the 
synthesis of milk proteins and enzymes important to milk formation (Hartmann and 
Cregan 2001; Neville et al. 2001). While milk secretion through the ducts has not yet 
set in, increased concentration of lactose and α-lactalbumin can be detected in the 
plasma (Arthur et al. 1991; Atwood and Hartmann 1995) and lactose can also be 
detected in the urine (Atwood and Hartmann 1995). Phase II begins with the onset of 
copious milk secretion, typically within the first four days postpartum, following the 
drop in circulating progesterone levels (Atwood and Hartmann 1995; Neville 1999; 
Hartmann and Cregan 2001; Neville and Morton 2001).  
 
1.1.1.1 Regulation of Lactogenesis 
It has been well established that abrupt changes in the plasma concentrations of the 
hormones of pregnancy set lactogenesis in order. In a developed mammary epithelium, 
the constant presence of prolactin near 200ng/ mL and a fall in progesterone is essential 
for the onset of lactogenesis II (Kuhn 1983). In humans, this is illustrated when removal 
of placenta, the source of progesterone is necessary for initiation of milk secretion 
(Neifert et al. 1981) and that delayed lactogenesis occurs when placental fragments, 
capable of secreting progesterone is retained (Neifert et al. 1981). Besides the fall in 
progesterone, other hormones are required for the onset of lactogenesis II. Prolactin is 
essential for sustained lactation after the fall in placental lactogen that accompanies the 




decline in progesterone levels post removal of placenta (Neville and Morton 2001). 
However, the amount of milk secreted is not directly related to the concentration of 
prolactin in the blood, but rather local mechanisms within the mammary gland (Neville 
1999).  One of them, the protein factor, FIL is secreted with the other milk components 
into the alveolar lumen and acts by reversible blockade of constitutive secretion in the 
mammary epithelial cell (Peaker and Wilde 1996). Thus, an increase in emptying brings 
about an increase in the rate of milk synthesis over a period of days and conversely, 
decreased emptying brings about a reduction in milk synthesis. 
 
1.1.1.2 Changes during Lactogenesis 
Milk production starts at less than 100mL/ day on day one postpartum and increases to 
an average of 500mL by day four. During this period, milk composition alters 
massively as lactogenesis progresses from Phase I to Phase II, with the fall in sodium 
and chloride concentrations and a rise of lactose concentration (Neville et al. 1991). 
Concurrently, the concentrations of secretory immunoglobulin A and lactoferrin 
increase dramatically and remain high up to 48hrs after birth (Lewis-Jones et al. 1985). 
Their concentrations fall rapidly after day two partly due to dilution as milk volume 
secretion increases, but their secretion rate is still substantial (2–3g/ day for each protein 
throughout lactation). Oligosaccharide concentrations are also high in early lactation, 
comprising as much as 20g/ kg of milk on day four (Coppa et al. 1993; Coppa et al. 
1999), falling significantly to a level of 14g/ kg of milk on day 30. The substantial 
volume increase between 36hrs and 96hrs reflects a massive increase in the rates of 
synthesis and/ or secretion of almost all the components of mature milk (Neville et al. 
1991), including but not limited to lactose, protein (primarily casein) (Patton et al. 1986; 
Chen et al. 1998), lipid, calcium, sodium, magnesium, and potassium.  




1.1.1.3 Factors Associating with Lactogenesis 
There are numerous factors potentially associated with lactogenesis in humans which 
can be summarised in the following table.  
 
   Biological     Behavioural 
Maternal Parity     Motivation to breastfeed 
   Mode of Delivery   Social support 
   Labour Experience   Nursing frequency 
   Body mass index   Use of supplements 
   Smoking    Use of pacifiers 
   Breast/ Nipple abnormality  Breastfeeding experience 
   Breast/ Nipple surgery   
   Illness 
   Anxiety and stress 
   Retained placental fragments 
   Hypothyroidism, hypopituitarism 
   Ovarian theca-lutein cyst 
   Polycystic ovarian syndrome 
   Postpartum haemorrhage with Sheehan’s syndrome 
   Hormonal contraceptive administration first week postpartum 
 
 Infant  Birth weight    Temperament 
   Gestational Age   Suckling style 
   Suckling ability    
 
 
Table 1-1: Factors associated with lactogenesis. Adapted from (Dewey et al. 2001; 
Hurst 2007). 
 
The problem with failed lactogenesis can be subdivided into preglandular, glandular 
and post glandular (Morton 1994). An example of preglandular would be hormonal 
causes, such as retained placenta or lack of pituitary prolactin. Glandular causes might 
be surgical procedures, such as reduction mammoplasty or, possibly, insufficient 
mammary tissue. Lastly, postglandular would be any cause for ineffective or infrequent 
milk removal. This latter aspect has received insufficient attention. Observational 
studies have suggested that milk removal and/ or effective suckling are necessary for 
milk volume increase, at least in a proportion of females (Aperia et al. 1979; Morton 




1994), although this is in contrary with other studies. Kulski et al suggested that milk 
removal was not necessary (Kulski et al. 1978) and Chen et al showed that it was the 
time of the first feeding and the breastfeeding frequency on day 2 postpartum that was 
positively correlated with the milk volume (Chen et al. 1998).  
 
Two other major risk factors have been shown to be responsible for delayed 
lactogenesis: long duration of labour (for natural deliveries) and urgent caesarean 
section, both of which are strongly related to the amount of stress experienced by both 
the mother and baby during parturition (Chen et al. 1998; Dewey 2001). These results 
affirm firstly, the impairing of milk ejection reflex by affecting oxytocin release during 
a feed and secondly, both maternal and fetal stress during pregnancy and childbirth are 
associated with impaired lactogenesis. Emotional stress postpartum is found to impair 
lactogenesis as well, highlighting the importance of additional care and guidance for 
women who experience highly-stressful circumstances (Dewey 2001). Initiation of 
lactogenesis has been found impaired with poorly-managed diabetes (Neville et al. 1988; 
Arthur et al. 1989; Neubauer et al. 1993) and high body mass (Hilson et al. 1997), 
which have more recently been found to be associated with delayed lactogenesis II 
(Chapman and Perez-Escamilla 1999; Chapman and Perez-Escamilla 2000).  
 
Dissecting the mechanisms in which various factors influence lactation and 
breastfeeding is required as a basis for analysing the possible effects on this process in 
situations where delayed or failed lactogenesis is suspected. Recognizing when and how 
to intervene in order to properly detect and assess the degree to which lactation is 
compromised will allow for individualized interventions and appropriate follow-up 
which would be invaluable in managing the initiation of breastfeeding, especially in 




mothers of sick infants as well as in sick mothers of well infants (Neville and Morton 
2001; Hurst 2007). A collaborative effort between nurses, midwives, physicians, and 
lactation consultants will serve each mother with a coordinated and individualized plan 
of care for her unique situation. In addition, with the knowledge of the micro changes 
accompanying lactogenesis, as well as identifying compounds if any that may hinder 
milk secretion would provide a new index for predicting which women are likely to 
have problems initiating lactogenesis II (Neville and Morton 2001). On the whole, all 
these collectively would bring forward treatment and management soonest possible and 
on top of that, helping the mother recognize her full lactation potential, even when it 
falls short of exclusive breastfeeding, can result in a feeling of success and 
accomplishment (Hurst 2007). 
 
1.1.2 Lactation 
Lactation is the process of milk secretion which is prolonged as long as milk is removed 
from the gland on a regular basis. It is the defining characteristic of all animals of the 
class Mammalia, whereby there is the production of an externally secreted fluid, milk 
that is designed specifically to nourish the young of the species. In humans, breast milk 
has been recognized as the preferred nutrition for infants and exclusive breastfeeding up 
to six months. Thereafter, continued breastfeeding complemented by solid foods being 
recommended up to 2 years of age by international agencies and several US health 
organisations (World Health Organisation 1989; Institute of Medicine 1991; American 
Academy of Paediatrics 1997). 
 




1.1.2.1 Milk Volume Production 
Milk secretion is a robust process that proceeds under normal physiologic principles as 
previously outlined [in Section 1.1.1] in at least 85% of postpartum women. Initiated at 
less than 100mL per day, it increases 36hrs after delivery, and continues to increase 
dramatically for the next 48hrs before plateauing off around 4 days postpartum (Arthur 
et al. 1989; Neville 1999). A meta-analysis of the volume of milk secreted by 
exclusively breastfeeding women showed that milk volume is remarkably fairly 
constant at about 800 mL per day in different populations throughout the world (Neville 
1999).  
 
With assistance in the techniques of breastfeeding, anecdotal evidence suggests that at 
least 97% of women can successfully breastfeed their infants. The lack of success is 
largely due to the ease in substituting breast milk with formula when infants have yet to 
adapt to the breast, at least in the Western countries (Neville 1999). However, in recent 
years, the increasing awareness of the benefits of breast milk is causing a paradigm shift 
in terms of proportion of women choosing to breastfeed who are further encouraged by 
the increasing number of support groups worldwide.  
 
1.1.2.2 Effects of Lactation 
1.1.2.2.1 Effects on breastfeeding female 
In humans, the metabolic demands of breastfeeding increase the maternal metabolism 
by about 20% of the usual metabolic output of a moderately active woman (Prentice 
and Whitehead 1987). Hence, very little adjustment, for instance, a slight increase in 
food intake or a slight increase in weight loss, is needed to compensate for the increase 




in metabolic needs for secretion of breast milk (Neville 1999). While the adjustment in 
food intake is not drastic, calcium loss from their bones by the postpartum female 
would be significant (Cross et al. 1995; Krebs et al. 1997), due to the lack of oestrogen 
during the period of postpartum infertility when menses have yet to be resumed and 
therefore, food intake has to be adjusted to ensure increased calcium intake. 
 
It has been suggested that breastfeeding reduces stress levels in lactating females. Using 
rodents, it was found that a reduction in the usual endocrine response to stress including 
adrenocorticotropic hormone (ACTH), corticosterone, catecholamines, oxytocin and 
prolactin was found to be associated with lactation (Neville 1999). This result was 
similar in lactating women when their plasma levels of ACTH, cortisol and adrenaline 
were compared against a matched group of nonlactating women after graded treadmill 
exercise to simulate stress (Altemus et al. 1995). 
 
There have also been several studies highlighting the protective role of breastfeeding 
with regards to breast (Byers et al. 1985; McTiernan and Thomas 1986; Yuan et al. 
1988; Layde et al. 1989; Yoo et al. 1992; Yang et al. 1993; Enger et al. 1997; McCredie 
et al. 1998) and ovarian cancers (Risch et al. 1983; Rosenblatt and Thomas 1993; 
Shoham 1994). With regards to breast cancer, it was found that the level of relative risk 
reported varied from approximately 0.54 to 0.85 for the first three to six months of 
breastfeeding, from 0.39 to 0.71 at twelve months of breastfeeding, 0.4 to 0.72 for more 
than two years, and 0.35 for more than six years (Labbok 2001). The biological 
reasoning for this association include differences in cellular milieu (Kennedy 1994) and 
the lack of maturation of the mammary gland. Back in 1983, Risch et al found a 
protective effect of lactation (relative risk of 0.79 per year of lactation) in a 




retrospective study of newly diagnosed patients with epithelial ovarian cancer although 
it was later proved to be accounted by the inhibition of ovulation through high prolactin 
levels generated by active breastfeeding (Risch et al. 1983). Subsequently by 1994, 
there were various conflicting findings on the protective effect of breastfeeding with 
ovarian cancer, with a balance towards a protective effect of breastfeeding in reducing 
risk of ovarian cancer (Shoham 1994). 
 
One of the most marked effects of lactation is its effect on fertility. Due to the presence 
of the suckling stimuli, luteinising hormone secretion remains in its suppressed state 
and secretion of ovarian steroids remains low. This results in natural contraception in 
the form of low fertility postpartum, in the presence of active breastfeeding (Neville 
1999). This postpartum suppression of fertility is believed to play an important role in 
birth spacing on a population basis in developing countries where prolonged 
breastfeeding is the norm and the use of supplementary feeding is delayed (Neville 
1999).  
 
1.1.2.2.2 Effects on infant 
There have been several studies reporting on the benefits of breast milk for the infant. 
These studies have reported a benefit of breastfeeding with respect to the reduction in 
the incidence and severity of infantile diarrhoea, respiratory and urinary tract infection, 
otitis media, Haemophilius influenzae meningitis, and other infections as well as the 
rate of sudden infant death syndrome (Pisacane et al. 1992; Owen et al. 1993; Baker et 
al. 1998; Wilson et al. 1998). Specifically, Baker and his colleagues found through 
analysing data from a survey of 8,501 women that breastfeeding for three or more 
months reduced the prevalence of wheeze and diarrhoea in the first six months of life 




(Baker et al. 1998). Longitudinal studies also found that the protective effect of breast 
milk is dose dependent (Duncan et al. 1993; Duffy et al. 1997; Scariati et al. 1997; 
Cushing et al. 1998). 
 
It is becoming evident that breastfeeding also protects infants against illness beyond 
weaning, as indicated by several studies that included the follow-up of infants beyond 
the first few months of life (Davis et al. 1988; Koletzko et al. 1989; Takala et al. 1989; 
Howie et al. 1990; Gerstein 1994; Dewey et al. 1995; Saarinen and Kajosaari 1995; 
Wright et al. 1995; Wilson et al. 1998). Long term benefits of breastfeeding have been 
associated with reduced risks of developing allergic diseases, Type I diabetes mellitus, 
Crohn’s disease and malignant lymphoma (Davis et al. 1988; Koletzko et al. 1989; 
Gerstein 1994; Saarinen and Kajosaari 1995).  Breastfed infants are also believed to be 
at an advantage with respect to their long-term cognitive development and lower rates 
of neurologic disabilities (Lucas et al. 1992; Rogan and Gladen 1993; Lanting et al. 
1994; Temboury et al. 1994).  
 
In addition to its nutritional, anti-infective, immunologic, and developmental effects, 
breastfeeding is unique for its mode of feeding with important advantages of hygiene 
particularly in developing countries as well as physical and emotional bonding of 
mother and child (Kunz et al. 1999; Rodriguez-Palmero et al. 1999).  
 
 




1.2 Breast Biology 
1.2.1 Anatomy 
Mammary tissue can be subdivided into the parenchymal and the stromal components. 
The parenchymal component is formed by a number of ‘treelike’ glandular structures 
derived from dichotomous branching of each of several ducts arising from the nipple. 
The major functional units of these glands are the lobular structures, situated at the end 
of the terminal ductules, which comprise several smaller blind ending ductules often 
referred to as terminal ductal lobulo-alveolar units (TDLUs), which has been defined by 
Russo and Russo as a cluster of approximately 11 small ductules or alveolar buds 
around a terminal duct that is embedded in specialized intralobular stroma (Russo and 
Russo 1987).  These TDLUs are lined by a continuous layer of luminal epithelial cells, 
which in turn are enmeshed by myoepithelial cells that contact the basement membrane.  
This entire structure is then surrounded by delimiting fibroblasts, and embedded in a 
specialized intralobular stroma (Howard and Gusterson 2000). These together with the 
adipose tissue and skin in the anatomical area constitute the stromal region (Mepham, 
1983). 
 
 During pregnancy, the terminal end ducts undergo further differentiation with the 
MaSC differentiating into alveolar epithelial cells which are arranged into single-layer 
spherical structures known as alveoli, ductal epithelial cells lining the ducts, as shown 
in Fig. 1.1 and myoepithelial cells that surrounds the alveoli, forming a layer separating 
the ductal and alveolar epithelial cells from the basement membrane. Each of the alveoli 
has a central lumen in which the synthesised milk is stored till time of release.  
 




Cells in the mammary gland lie in a collagenous connective tissue framework known as 
the extracellular matrix (ECM). Extracellular matrix of the mammary gland is a highly 
complex mixture containing collagen, fibronectin, laminin, glycosaminoglycans and 
others (Streuli 1993). The basement membrane of the secretory cells is also part of the 
ECM and is produced at least in part by the secretory cell itself.  
 
 
Figure 1-1 Schematic view of lobulo-alveolar clusters. Before puberty, the cells are 
arranged into terminal end ducts. Cap cells surrounding them are postulated to be 
multipotent stem cells (A). The terminal end ducts undergo differentiation during 
pregnancy forming alveoli. Alveolar and ductal epithelial cells that line the ducts of the 
clusters are surrounded by a layer of overlapping myoepithelial cells (B). (Adapted from 
(Woodward et al. 2005). 
 
1.2.2 Cellular Component of Mammary Gland 
1.2.2.1 Epithelial Cells 
Mammary ducts are bilayered tubes composed of inner luminal epithelial cells 
surrounded by myoepithelial cells, which are in turn surrounded by an extracellular 
basement membrane (Anderson and Clarke 2004).  
 
Luminal epithelial cells express the sialomucin MUC1, which is present on their apical 
membranes, whereas myoepithelial cells express the common acute lymphoblastic 




leukaemia antigen (CALLA) and smooth muscle actin (Gusterson et al. 1986; Taylor-
Papadimitriou et al. 1986; Taylor-Papadimitriou et al. 1992). In addition, each of these 
cell types also has a particular cytokeratin (CK) profile. Luminal epithelial cells express 
CK8 and CK18 while myoepithelial cells express CK14 (Taylor-Papadimitriou et al. 
1989). Luminal epithelial cells synthesise the various milk components and empty them 
into the lumen where they are stored. These cells are cuboidal with their apical surface 
thickly covered with microvilli about 0.1µm in diameter and up to 0.5µm in length 
(Pitelka et al. 1983). Myoepithelial cells surround the alveoli and ducts (Figure 1-1). 
These contractile cells are more elongated than secretory cells and they contract in 
response to oxytocin, releasing milk from the lumen of the alveoli (Linzell 1952). In 
addition to fostering oxytocin-induced milk ejection by virtue of their contractile 
activity, myoepithelial cells are the cells that actually contact the basement membrane 
directly and are required for the production of ECM, including laminins. Thus they are 
ideally situated to transmit structural morphogenetic information from the basement 
membrane to the luminal epithelia. Indeed, isolated luminal epithelial cells (which do 
not form their own basement membranes) fail to form properly polarized hollow 
spheres when cultured in type I collagen gels and instead form solid lumen-less 
structures with reverse polarity unless myoepithelial cells are also added, in which case 
they do form aptly polarized, hollow, bilayered acinar-like structures (Gudjonsson et al. 
2002a). 
 
Apart from the two major epithelial cell types in the mammary gland, there also exists a 
third and less common intermediate population, the MaSC (Anderson and Clarke 2004). 
Mammary tissue has to be equipped with a ready source of MaSC to replenish the 
mammary gland through cycles of pregnancy, lactation and involution. This idea was 




first suggested nearly three decades ago by the ability of a clonal murine epithelial cell 
line to differentiate into two different cell types (Bennett et al. 1978). Since then, the 
presence of mammary stem/ progenitor cells in the mammary gland has been 
established (Smith 1996; Gudjonsson et al. 2002b). The stem cell compartment within 
the breast was demonstrated to be localised within the luminal epithelial compartment 
(Pechoux et al. 1999; Gudjonsson et al. 2002a), a result which is consistent with an 
earlier finding that proliferating cells are found in the luminal population as cell 
division and expression of antigens associated with proliferation being exceedingly rare 
in the myoepithelial cell type (Joshi et al. 1986). These cells are responsible for the 
multiple cycles of proliferation and involution of the mammary tissue when necessary 
and will be further discussed in detail in Section 1.4.1. 
 
1.2.2.2 Non-epithelial Cells 
Apart from the epithelial cells which are responsible for the production and secretion of 
milk, capillary endothelial cells are also abundant in the highly vascularised mammary 
tissue. An extensive lymphatic system with lymphocytes and monocytes being common 
infiltrators is also present. The mammary tissue contains a large component of 
adipocytes in the stroma within populations of fibroblasts, which have been 
demonstrated in the pregnant murine models to transdifferentiate into secretory 
epithelial cells (Morroni et al. 2004). 
 




1.2.3 Mammary Development 
1.2.3.1 The Stages of Development 
The mammary gland is one of the few tissues that undergo repeated cycles of 
development and regression in the adult animal. Development of the mammary gland is 
a highly dynamic and orchestrated process that occurs throughout postnatal life. 
Complete differentiation and maturation of each mammary compartment is a gradual 
process and has considerable variations between different individual woman, between 
each breast and even within each breast. Full differentiation of the mammary gland is 
only achieved in parous women (Hovey et al. 2002).  
 
The process of breast formation is initiated during embryogenesis, with the formation of 
the milk streak at week 4 post fertilisation, which progresses into a bilateral mammary 
ridge (or milk line) during weeks 5 and 6 and then followed by the appearance of 
distinct placodes. Between 7th and 8th weeks of gestation, the formation and ingrowth of 
mammary bulbs begins, with further inward growth of the mammary parenchyma 
commencing at the 9th week. Between the 10th and 12th weeks, initial budding of the 
nascent mammary gland will be observed followed by the indentation resulting in 
formation of epithelial buds with notches at the epithelial-stroma border  (Howard and 
Gusterson 2000; Hovey et al. 2002). A rudimentary ductal tree then forms by the 
branching of the parenchyma during the 13th-20th week which results in 15-25 epithelial 
strips or solid cords that eventually give rise to multiple galactophores at each nipple. 
During the latter stages of fetal development via the branching process and up to 32 
weeks, the solid cords become canalized by apoptosis of the central epithelial cells. 
Finally, development of end vesicles comprising a monolayer of epithelial cells occurs 
in association with restrained lobulo-alveolar development between the 32nd and 40th 




week of pregnancy (Hovey et al. 2002). Post-parturition, the infant breast undergoes 
menopausal-like involution whereby the ductal structures persist in a relatively 
quiescent manner until puberty, beyond which breast development in males and females 
diverge. 
 
At the onset of puberty, the female human breast undergoes variable amounts of 
terminal end buds (TEB) formation, duct elongation, dichotomous and lateral branching, 
terminal duct lobular unit formation and stromal expansion directed by concurrent 
modifications in hormones and growth factors across the various reproductive stages 
(Hovey and Trott 2004; Sternlicht 2006). The male breast on the other end, remains 
quiescent but capable of further development under certain circumstances from 
exogenous estrogens, liver failure and stimulation from drugs, resulting in 
gynecomastia (Sternlicht 2006).  
 
Further into the female’s lifespan, at the onset of pregnancy and associated changes in 
hormonal and local environment, alveolar development progresses with the mammary 
epithelial cells within the gland attaining their unique ability to synthesise various milk 
components. At the last stages of gestation, the distal portion of the mammary ducts 
develops into alveolar structures and mammary epithelial cells appear secretory, such 
that with parturition, functional lactogenesis can take place (Hovey et al. 2002; Hovey 
and Trott 2004). This process is driven by the systemic hormonal stimuli that elicit local 
paracrine interactions between the developing epithelial ducts and their adjacent 
mesenchyme, to be further discussed in Section 1.2.3.2 (Sternlicht 2006).   
 




Involution occurs when regular extraction of milk from the gland ceases. Milk stasis is 
the key signal for the alveolar secretory epithelial cell to undergo apoptosis and be 
removed by phagocytosis. The alveoli will collapse and by day 6, disintegrated 
completely, with both the stromal and epithelial components remodelled, while the 
ducts remain intact (Richert et al. 2000). This involves an orderly sequence of events 
including cessation of milk secretion, increased secretion of lactoferrin (Hartmann 
1973), opening of the tight junctions, apoptosis of the mammary epithelium (Strange et 
al. 1992), and changes in secretion of proteases (Lund et al. 1996), followed by the 
remodelling of the ECM, after which the gland returns nearly to its prepregnant state, 
after 3 weeks (Neville 1999; Anderson and Clarke 2004).  However, it appears that the 
human mammary gland does not revert to the virgin state but to a more differentiated 
form in terms of number of lobules in each TDLU (Russo and Russo 1987). It is 
believed that the reduction in breast cancer risk afforded by an early first full-term 
pregnancy may be related to the fact that the gland is left in a more differentiated state 
following involution (Russo et al. 2001). 
 
Eventually, the mammary gland undergoes another round of involution at menopause 
(Anderson and Clarke 2004). For this phase of involution, there is regression of ducts 
and lobules, and adipose tissue replaces the glandular epithelium and interlobular 
stroma with the eventual result of sparse scattering of atrophic acini and ducts through 
the tissue (Howard and Gusterson 2000). 
 




1.2.3.2 Regulators of Development 
Each stage of the differentiation process is tightly controlled by both soluble factors 
such as hormones and growth factors and the interactions of cells with the environment 
(Guyette et al. 1979; Topper and Freeman 1980; Hobbs et al. 1982). 
 
Briefly, the ductal tubes are compactly surrounded by the myoepithelial layer, 
preventing the direct interaction of the ductal epithelium with the basement membrane 
in the nulliparous female (Figure 1-1). Increased levels of progestins, oestrogens and 
placental lactogen during pregnancy allow the budding of the alveolar epithelium. This 
brings most alveolar epithelial cells in close proximity to the basement membrane as 
myoepithelial cells build a loose network that wraps the alveolar structures. Involution 
of the mammary gland occurs when lactation ceases. The alveolar structure starts to 
disintegrate and the basement membrane is removed by ECM-degrading 
metalloproteinases (Knight 1995).  
 
1.2.3.2.1 Hormonal control 
For the hormonal influence, several studies have shown that oestrogen, progesterone, 
prolactin (PRL), growth hormone (GH), and thyroid hormones are essential for ductal 
elongation, branching, and alveolar budding, specifically, oestrogen and its 
corresponding receptor required for adolescent branching while progesterone and its 
corresponding receptor is required for adult tertiary side-branching (Sternlicht 2006).  
Adrenal steroids, prolactin (PRL), growth hormones (GH), thyroid hormones, oxytocin, 
and insulin are required for complete lobuloalveolar development and milk synthesis, 
secretion, and lactation. Some of these hormones (oestrogen, progesterone, PRL, and 




GH) appear to be inductive while others play a more permissive role (Hovey et al. 
2002). 
 
1.2.3.2.2 Interaction with environment 
Apart from hormonal control, it has also been established that there are several other 
factors involved in branching morphogenesis, such as epidermal growth factor (EGF) 
signalling through its ligand (Coleman et al. 1988; Kenney et al. 2003) and autocrine 
signalling through ECM-mediated regulation (Fata et al. 2004). Numerous culture-
based studies show that, in addition to providing a structural foundation for cells, ECM 
components convey contextual information through cellular adhesion molecules, such 
as integrins, that transmit external ECM-derived signals to the cell interior. Indeed, the 
three-dimensional ECM environment has been shown to affect virtually all aspects of 
cell behaviour, including cell shape, proliferation, survival, migration, differentiation, 
polarity, organization, and branching. In addition to their direct effects, various ECM 
components bind and sequester other signalling molecules that affect branching, such as 
amphiregulin, FGFs, Wnts, TGF-R, and IGF-binding proteins 1 to 6. Thus enzyme-
mediated ECM remodelling can remove existing ECM signals, reveal hidden structural 
information, and release otherwise sequestered signalling molecules. Indeed, ECM 
degrading matrix metalloproteinase (MMPs) appear to have a path-clearing role in 
branching morphogenesis as well as an indirect cell signalling role that may reflect their 
ability to alter existing ECM signals, generate bioactive ECM fragments (for example 
cryptic integrin-binding sites on fibrillar collagen and a laminin-5 fragment that elicits 
epithelial cell motility), cleave cell–cell adhesion proteins (for example E-cadherin), 
degrade cell surface receptors (for example FGFR1), release ECM-bound growth 




factors, inactivate IGF-binding proteins, activate latent TGF-1, and recruit other cell 
types to the surrounding stroma (Sternlicht and Werb 2001; Wiseman et al. 2003). 
 
The importance of interaction of cells with the environment is further affirmed that 
tissue transplantation studies in which mammary epithelium and salivary mesenchyme 
(Sakakura et al. 1976) or skin epithelium and mammary mesenchyme (Cunha et al. 
1995) were recombined demonstrate that mesenchymal cues control the branching 
pattern of the epithelium, regardless of epithelial origin. 
 
1.3 Composition of Breast Milk 
Human breast milk (HBM) has been humankind’s first food for as long as the human 
race has existed. It is a complex biological fluid and contains many different 
constituents, which provide nutrients and also protection of the newborn against 
diseases before the immune system of the newborn is established. Being extremely 
dynamic in nature, HBM varies with increasing time after the birthing process, during 
each nursing feed, and with the mother’s diet and certain diseases, adjusting to match 
the changing needs of the developing infant (Kunz et al. 1999). It provides a balanced 
nutrient composition as well as a number of conditionally essential nutrients and at least 
45 different types and classes of bioactive factors, such as enzymes, hormones, and 
growth factors. Most of them play a role in supporting infantile growth and 
development (Bates and Prentice 1994; Koldovsky 1995).  All contituents of HBM will 
be briefly discussed in this section. 
 





Lactose is the major carbohydrate in HBM. The most important role of lactose is to 
regulate the water content in milk since its synthesis brings in a flow of water that 
dilutes other milk constituents like protein and fat (Davies 1983). It has been suggested 
that lactose aids the growth and development of the brain as one of its subunits, 
galactose is known to form a large part of the brain matter (Davies et al., 1983). Lactose 
also forms weak complexes with metal ions such as Ca2+ and Fe3+, facilitating intestinal 
absorption of them by the infant (Davies 1983).  
 
Human milk oligosaccharides may act as soluble receptors for different pathogens, thus 
increasing the resistance of breastfed infants to these potential pathogens (Kunz et al. 
1999). The complex mixture of oligosaccharides that is present only in minute amounts 
among other uses, act as inhibitors of bacterial adhesion to epithelial surfaces, playing 
an important role in preventing infectious diseases in the newborn infant. They also 
seem to promote the development of a bifidus flora (Kunz et al. 1999), which can 
inhibit the growth of Escherichia coli and consequently protect breast-fed infants 
against gastrointestinal disease (Azuma et al. 1984).  
 
HBM is also reported to contain glucose, galactose and fructose, which are possibly 
present as residuals of metabolic processes (Sheibak et al. 1978). 
 
1.3.2 Lipids 
Mammary alveolar cells synthesise milk fat from circulating lipids derived from the 
maternal diet as well as from maternal body stores. In addition, part of the milk fat can 
be synthesized de novo in the mammary gland from glucose (Thompson and Smith 




1985). Synthesis of milk fat is stimulated by emptying of the breast through nursing and 
by prolactin secreted from the anterior lobe of the pituitary gland. The alveolar cells 
package and secrete the lipids into the lumen in the form of milk fat globuli. These have 
a hydrophobic core consisting of triglycerides, cholesteryl esters, and retinyl esters and 
are covered with bipolar or amphipathic compounds including phospholipids, proteins, 
cholesterol and enzymes in a loose network termed the milk fat globule membrane 
(Koletzko and Braun 1991). 
 
The level of fat in HBM has been reported to vary from 0.4% to 10% rendering it the 
most variable of all milk components. 98% of lipids in human milk fat are 
triacylglycerols, followed by phospholipids (0.7%), cholesterol (0.5%), free fatty acid 
0.08%, monoacylglycerols (trace) and cholesterol esters (trace) (Bracco et al. 1972; 
Bitman et al. 1983). The level of fat in HBM is also influenced by stage of lactation, 
time of milk sampling, frequency of milk output, stress and level of mammary gland 
stimulation prior to feeding (Packard 1982). Interestingly, studies have shown that there 
are no major differences in lipid composition in milk from term and preterm mothers, 
although there were more medium- and intermediate-chain fatty chains (10:0 compared 
to 14:0) in preterm than term milk (Bitman et al. 1983; Genzel-Boroviczeny et al. 1997).  
 
The products of lipolysis and their monoglycerides after the digestion of triglycerides 
are potent microbicides that assist in controlling of infections in the stomach and small 
intestine (Hernell et al. 1989). Phospholipids in HBM, can be subdivided into major 
classes: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, 
phosphatidylinositol and sphingomyelin and these phospholipids, being bipolar, act as 
emulsifiers to help maintain the globule emulsion (Jensen 1996).  Lastly, the several 




classes of sphingolipids and glycolipids, which are collectively known as gangliosides 
contribute to the host defense system in human milk by binding to cholera and other 
toxins (Laegreid et al. 1986). 
 
1.3.3 Proteins 
Human milk proteins are a source of peptides, amino acids and nitrogen for the infant, 
but also in the protein fraction reside other properties of HBM that further benefit the 
developing infant.  
 
Protein in HBM comprises 40% casein and 60% whey proteins. Caseins associate under 
ionic conditions of milk to form micelles and these micelles are a source of amino acids 
for the infant. They also enable calcium and phosphorus to be transported in a stable 
form in milk (Davies 1983). Whey comprises a variety of proteins that supplement the 





The main immunoglobulin in human milk is immunoglobulin A (IgA), although 
significant levels of lgG, IgM and IgD have also been detected (Goldman and 
Goldblum 1989). IgA exists in the secretory form (sIgA) in HBM and protects the 
infant against a range of enteric and respiratory pathogens; blocking the adhesion of 
potential pathogens to mucosal surfaces, hence preventing their colonisation and 
neutralising the toxins from microorganism (Telemo and Hanson 1996). It also prevents 
translocation of gut bacteria through the epithelial barrier, causes the agglutination of 
bacteria, and possibly offers protection against sepsis and function as natural 




immunising agents that sensitises the infant to foreign antigens including microbial 
agents (Maxson et al. 1995; Steinwender et al. 1996; Garofalo and Goldman 1999); 
(Wold et al. 1994). As the sIgA molecule is too large to be filtered by the kidneys, the 
presence of a significantly higher output of intact IgA in urine of breastfed infants 
suggest that HBM can stimulate the production of IgA in the recipient infant (Goldblum 
et al. 1989; Prentice 1996).  
 
1.3.3.2 Lactoferrin 
The amount of lactoferrin in HBM declines throughout lactation, from 5-6mg/ mL in 
colostrum to 1.5mg/ mL in mature milk, defined to be milk produced beyond 10 days 
post delivery. Almost all lactoferrin in HBM is in the form of apo-lactoferrin, and it is 
this iron-free form that competes with siderophilic bacteria for ferric iron, disrupting 
their proliferation and preventing infection by these iron-requiring organisms (Brock 
1980; Stuart et al. 1984).  More recently, it was found that lactoferrin causes the release 
of lipopolysaccharide molecules from bacteria cell wall and sensitises the 
microorganisms to antibiotic and attachment by lysozyme (Packard 1982; Ellison and 
Giehl 1991). It also inhibits the complement system (Morgan et al. 1975), suppresses 
cytokine release from macrophages stimulated with bacterial products (Mattsby-Baltzer 
et al. 1996), suppresses in vitro antibody production (Duncan and McArthur 1981) and 
T lymphocytes’ proliferative response to alloantigens and phytohemagglutinin (Richie 
et al. 1987). It has also been shown to bind to specific DNA consensus sequences that 
can confer lactoferrin-induced gene transcription (He and Furmanski 1995), and has 
been suggested to enhance iron absorption (Cox et al. 1979).  
 





Prolactin augments the development of B and T cells (Gala 1991) and modulates 
differentiation and function of gut-associated lymphoid tissue, such as intraepithelial 
lymphocytes that express more prolactin receptors than neonatal splenocytes (Ellis et al. 
1997). In addition  to being a mitogen for T lymphocytes in culture (by induction of  
interleukin-2 and interleukin-2 receptors (Ellis and Picciano 1992; Grosvenor et al. 
1993), milk-borne prolactin is essential for neuroendocrine development during a 
critical period of 2-5 days after birth in rats (Grosvenor et al. 1993).  
 
 
1.3.3.4 Other Whey Proteins 
A host of nucleotides are also present in HBM. Using animal models, it has been shown 
that nucleotides enhance mucosal development by stimulating growth and maturation of 
the gastrointestinal tract and intestinal repair after diarrhoea (Uauy et al. 1990; Bueno et 
al. 1994). The immunomodulatory activity of nucleotides has been associated with the 
enhancement of T-cell maturation and function (Van Buren et al. 1985), improvement 
of delayed cutaneous hypersensitivity and alloantigen-induced lymphoproliferation 
(Van Buren et al. 1983) and partial resistance to infection with bacteria or other 
pathogen (Kulkarni et al. 1986). 
 
Some soluble cell adhesion molecules and their ligands detected in HBM aid in the 
defence against pathogens as well (Buescher and Malinowska 1996; Schwertmann et al. 
1996). 
 
Several cytokines, chemokines and colony-stimulating factors have been discovered in 
human milk. Interleukin 6 is believed to enhance IgA1 and IgA2 production (Fujihashi 




et al. 1991) by the intestinal and bronchial epithelial cells which expressed the 
appropriate receptor (Shirota et al. 1990; Takizawa et al. 1996). Interleukin 10 exerts 
anti-inflammatory effect in the form of suppressing the functions of macrophage, T-cell 
and natural killer cells’ function by blocking inflammatory cytokine synthesis and 
several accessory cell functions (Kuhn et al. 1993; Moore et al. 1993; Garofalo et al. 
1995).  It also induces activated B cells to produce large amounts of IgM, IgG and IgA 
(Rousset et al. 1992). Together with interferon-γ, they modulate in vitro epithelial 
integrity and ion transport along the stomach wall of the infant, suggesting the 
expression of functional receptors for these cytokines by human epithelial cells (Archer 
and Johnson 1978; Adams et al. 1993; Madsen et al. 1997).  Among the chemokines 
present, interleukin 8, growth-related peptide-α and RANTES were found to be the 
most potent chemotactic factors for intestinal intraepithelial lymphocytes (Ebert 1995). 
 
There are also proteins in the form of enzymes and growth factors in HBM. Alpha-
lactalbumin, alpha-amylase, bile salt stimulated lipase, α1-antitrypsin and 
antichymotrypsin aid digestion in the infant (Ebner and Schanbacher 1974; Lindberg et 
al. 1982; Packard 1982) with other functional enzymes like antiproteases, sulfhydryl 
oxidase, gamma-glutamyltransferase and xanthine oxidase whose functions are 
described briefly in Table 1-2. The large array of growth factors present in HBM are 
also tabulated and categorised in Table 1-3. 
 




Enzyme   Function    Reference 
Antiproteases  Protect bioactive proteins (enzymes,      (Hamosh 1995) 
   immunoglobulins) from hydrolysis in  
   milk and in intestine of newborn 
 
Sulfhydryl Oxidase Maintain structural and functional      (Isaacs et al. 1984) 
   integrity of milk proteins, enzymes   
   and immunoglobulins 
 
γ-glutamyltransferase  Involved in endo and/ or exocytotic       (Binkley et al. 1975) 
   transport of proteins     
 
Xanthine Oxidase Aid in secretion of milk fat droplets     (Mather and Keenan 1983) 
   by peroxidising lipids     
 





A. Hormones and other substances with growth-promoting potential assayed in milk 
 1. Epidermal growth factor 
 2. Insulin 
 3. Thyroxine 
 4. Cortisol 
 5. Luteinizing hormone-releasing hormone 
 6. Prostanglandins 
 7. Transforming growth factors 
 
B. Demonstrated in vitro effect on growth of cells or tissues 
 1. Epidermal growth factor 
 2. Prostanglandins 
 3. Transforming growth factors 
 4. Lactoferrin 
 5. Granulocyte-colony stimulating factor 
 6. Macrophage-colony stimulating factor 
 7. Granulocyte-macrophage-colony stimulating factor 
 8. Bifidobacterium bifidum growth factors A and B 
 
Table 1-3: Growth factors present in HBM.  
Edited from (Morriss 1986) and (Garofalo and Goldman 1998) 





The vitamin content of HBM is variable and their level depends on the interrelation of 
several factors like diet, stage of lactation, alcohol or drug use of which, the general 
health of the mother, particularly her diet is perhaps the most significant and pervasive 
factor. Vitamin A, E and K are present in HBM in significant amounts to exert their 
respective functional roles which range from aiding the infant’s growth and 
development (Sommer et al. 1986; De Sole et al. 1987) to protecting against free 
radicals (Tappel 1965; Lucy 1972; Rodriguez-Palmero et al. 1999) and contributing to 
the coagulation process by supporting the synthesis of the relevant proteins (Rodriguez-
Palmero et al. 1999). 
 
1.3.5 Minerals 
Sodium, potassium and chloride are the prevalent monovalent ions in HBM. The 
concentrations of these monovalent ions in HBM regulate in part, the opening of the 
tight junctions between epithelial cells (Atkinson et al. 1995). Calcium is essential for 
the development of bones, muscle contraction, the transmission of nerve impulses and 
clotting of blood (Packard 1982). Trace minerals in HBM include cobalt, manganese, 
molybdenum, aluminium, barium, chromium, nickel, copper, iodine, boron, fluorine, 
zinc, bromine, iron, selenium, strontium and rubidium. The major factor affecting 
concentration of minerals is advancing duration of lactation, which is associated with a 
decrease in sodium and an increase in potassium. Chloride drops over time, whereas 
calcium, free phosphate and magnesium increase (Rodriguez-Palmero et al. 1999). 
Maternal age, parity and lactation history also account for the variability of trace 
element concentrations (Howell et al. 1986). 






The study of cells in human milk, first mentioned in 1844, has since then been studied 
extensively (Hamosh 2001). Epithelial cells, colostral cells, polymorphonuclear 
leukocytes, mononuclear phagocytes and lymphocytes have been reported in milk 
(Smith and Goldman 1968; Crago et al. 1979). The cell concentration and predominant 
cell type vary with duration of lactation and presence of breast inflammation.  
 
1.3.6.1 Immune Cells 
Colostrum defined as milk from day 1 to day 4 postpartum, contains 105 to 5x106 
leukocytes per mL of milk (Buescher and Pickering 1986). This concentration drops to 
the range of 105 per mL within the next six days of breastfeeding. The types of 
leukocytes found in HBM include macrophages, lymphocytes and polymorphonuclear 
leukocytes, with neutrophils and macrophages accounting for 90% of leukocytes in 
HBM (Xanthou et al. 1995). The neutrophils and macrophages present appear to be 
activated and were able to phagocytose and kill bacteria and fungi and they were also 
able to elicit antibody-dependent activity (Xanthou 1997). These cells also synthesise 
complements, lysozyme and lactoferrin, which acts synergistically to the cells. 
 
Lymphocytes, though present at a much lower proportion, are also consistently found in 
HBM with T cells accounting for 80% of the total number of lymphocytes (Xanthou et 
al. 1995).  Present in the activated form (Wirt et al. 1992), they were found to be less 
efficient in their cytotoxic capability when compared against the peripheral cells of the 
same individuals (Nair et al. 1985) but capable of generating  certain lymphokines and 
growth factors (Skansen-Saphir et al. 1993). B lymphocyte deficient mice were able to 




avoid severe infections when breastfed by normal mouse (Arvola et al. 2000) thus 
suggesting that maternal lymphocytes compensate for the developmental delay of the 
infant (Goldman et al. 1998). Maternal lymphocytes in HBM have been shown to enter 
the circulation of the offsprings, presenting themselves in the intestinal mucosa, lymph 
nodes and ducts (Weiler et al. 1983; Slade and Schwartz 1987; Jain et al. 1989; Arvola 
et al. 2000). This suggests that lymphocytes from milk may be able to induce not only 
local and also a systemic immune response (Xanthou 1997). Phagocytes count falls 
after 4 weeks of lactation, beyond which 90% of the cellular content in breast milk are 
epithelial cells (Brooker 1980).  
 
1.3.6.2 Epithelial Cells 
Three types of epithelial cells have been recognised in HBM, namely the secretory, 
myoepithelial and ductal cells. They have been described in detail in an earlier section 
(1.2.2). In HBM, secretory cells were commonly found up to 110 days postpartum, 
while the ductal cells were rarely encountered after eight days (Brooker 1980). It has 
been suggested that the presence of these epithelial cells in milk provides a means of 
evacuating dead cells which have reached the end of their secretory life although 
through trypan blue exclusion, it was found that more than 90% of these cells are viable 
(Gaffney 1982; Thompson et al. 1998). Whether these epithelial cells are present in 
HBM purely due to mechanical sloughing during milk expression or due to a yet-
unknown functional role, similar to the leukocytes present are an intriguing question 
worth pursuing. In addition to the biological reasoning behind their existence, epithelial 
cells from HBM may have several functional uses: the establishment of cell lines for 
lactogenesis studies whereby they can constitute an in vitro system for the study of 
proliferation and differentiation of mammary epithelial cells as well as application in 




cancer research as most human breast tumours arise from the mammary epithelial cells 
that line the milk duct and milk-secreting-cells (Buehring 1972). 
 
1.4 Adult Stem Cells 
Stem cells are defined by their functional attributes. Typically, one would define the 
stem cells of a particular tissue as undifferentiated cells capable of proliferation, 
producing a large number of differentiated functional progeny and yet able to self-
maintain the population by exhibiting self-renewal. Stem cells can be subcategorized 
into cloned cells, embryonic, fetal and adult, depending on the source. Each of these has 
its own set of advantages and disadvantages of which ethical and legal concerns have 
been raised by cloning (Smaglik 2001; 2002; Check 2002), and the use of embryonic or 
fetal stem cells (Antoniou 2001). Adult stem cells, while avoiding the ethical and legal 
issues, however are believed to have much restricted potential. Historically, many adult 
tissues were thought incapable of regeneration until cells with regenerative capability 
were found in most adult tissues including the liver (Sell 1978; Thorgeirsson 1996; 
Michalopoulos and DeFrances 1997), intestines (Potten and Loeffler 1990), retina 
(Tropepe et al. 2000), skin (Watt 1998), muscle (Seale and Rudnicki 2000), central 
nervous system (Gage 2000), mammary glands (Ormerod and Rudland 1986) and 
others. Stem cells from adult tissues, now proven present, are still believed to be 
restricted in their capacity to produce cells from tissues other than the one they arose in 
(Slayton and Spangrude 2004). However, a number of studies have since challenged 
this view (Horwitz et al. 1999; Kaufman and Ildstad 1999; Krivit et al. 1999; Morroni et 
al. 2004), indicating that adult stem cells from various organs are actually highly plastic, 
and that they can differentiate into not only cells of their original source tissue, but also 
cells of unrelated tissue and even germ layers. These studies range from demonstrating 




bone marrow-derived cells forming hepatocytes (Petersen et al. 1999), myocytes 
(Gussoni et al. 1999) and even neurons (Mezey et al. 2000).  Apart from the highly 
plastic bone marrow-derived cells, reversible transdifferentiation between the epithelial 
cells and adipocytes in the mammary gland have also been established (Morroni et al. 
2004).  
 
In conclusion, adult stem cell biology is a front runner in the emerging field of 
regenerative medicine and in the following sections, two particular adult stem cells that 
are of relevance to my research question will be reviewed in detail. 
 
1.4.1 Mammary Stem Cells 
Mammary gland development and function would not be possible without tissue-
specific stem cells. The cycle of pregnancy-associated proliferation, differentiation, 
apoptosis, and remodelling, which can occur several times during the entire lifespan, 
can only be explained by the presence of a long-lived population of stem cells with a 
near-unlimited capacity to generate functional cells (Anderson and Clarke 2004).  
 
1.4.1.1 Evidence for Their Existence 
Although the existence of MaSC have long been postulated, it was not until 1959 when 
Deome demonstrated the reconstitution of mammary gland when isolated mammary 
epithelium from donor mice were transplanted into cleared mammary fat pads (Deome 
et al. 1959). The existence of MaSC was then further verified when Ormerod and team 
demonstrates that fragments of mouse mammary epithelium can give rise to complete 
glands when transplanted into the fat pads of syngeneic hosts cleared of their 
endogenous epithelium (Ormerod and Rudland 1986). Limiting dilution studies in 




which clones derived from single cells could be identified on the basis of their patterns 
of mouse mammary tumour virus viral integration have shown that an entire fully 
functional mammary gland could be derived from a single cell and that this single cell 
can give rise to both luminal epithelial and myoepithelial cell types, suggesting the 
presence of a self-renewing pluripotent stem cell in the mouse mammary gland (Kordon 
and Smith 1998). This is further affirmed by Shackleton and team who demonstrated 
the reconstitution of a functional mammary gland capable of producing milk proteins by 
a single stem cell (Shackleton et al. 2006), proving conclusively their presence. 
 
1.4.1.2 Location of the Putative Stem Cells 
It has been suggested that the cap cells of the TEBs in the mouse mammary glands 
during the pubertal development contain the population of multipotent stem cells. This 
postulation is based on the observation that these cells have a high mitotic rate and that 
they are capable of following two different fates: either they enter the body of the TEB 
and become luminal epithelial cells, or they migrate across along the outmost stratum of 
the attached duct to become myoepithelial cells (Anderson and Clarke 2004). Although 
the human mammary gland has a TEB-like structure during pubertal development, it 
does not have a similar arrangement of cap and body cells, making it unclear whether 
the population of stem cells reside in the TEB-like structure (Anderson and Clarke 
2004). 
 
It was postulated that the MaSC should be those intermediate between the epithelial and 
myoepithelial cells which occur in growing ductal structures, particularly the TEBs. 
This is because they are able to give rise to both ductal epithelial cells and 
myoepithelial, the latter by an irreversible process (Rudland et al. 1997). The former 




ductal epithelial cells subsequently differentiate normally into alveolar cells in a 
reversible manner or under certain pathological conditions give rise to squamous cells 
(Rudland et al. 1997). In studies conducted by other groups, it was shown that mixed 
colonies were only obtained when CK8- and CK18-positive cells were plated and never 
when common acute lymphoblastic leukaemia antigen (CALLA)-positive myoepithelial 
cells were used (Stingl et al. 1998). Collectively, this suggests that the most likely 
candidates for stem cells in the mammary gland reside alongside the luminal epithelial 
cell population, and not within the myoepithelial cell population (Anderson and Clarke 
2004). 
 
1.4.1.3 Characterisation of Mammary Epithelial Stem Cells 
Early searches for mammary-specific stem cell markers  were based on the observations 
of Smith and Medina that mammary epithelial explants contained pale or light-staining 
cells, and that only these cells, which exist both in small and large forms enter mitosis 
when placed in culture (Smith and Medina 1988; Chepko and Smith 1997). Small light 
cells were described as mammary epithelial stem cells based on the presence of mitotic 
chromosomes, lack of any specialized organelles, and their basal location within the 
gland. Their nuclei were also found to contain dense clumps of heterochromatin. These 
cells were present in side-by-side homogenous pairs as well as heterogeneous pairs, 
suggesting their ability to undergo symmetric and asymmetric division (Welm et al. 
2003). Morphological studies of the developing implants using immunocytochemical 
and ultrastructural techniques have suggested the presence of these stem cell 
populations in the basal cell layers of ducts and end-bud. The cells populations may be 
the basal clear cells (Smith and Medina 1988) or a cap cell type intermediate in 
morphology between epithelial and myoepithelial cells (Williams and Daniel 1983; 




Ormerod and Rudland 1986; Rudland 1991). The location of the stem/ progenitor cells 
was further affirmed by a more recent study where cells of the regenerative 
compartment of the mammary gland, which is also the basal epithelial layer stained 
positive for nestin (Li et al. 2007). 
 
Various methodologies have been employed to identify and characterise these 
mammary stem/ progenitor cells but bona fide mammary stem cell markers have 
remained elusive. In mice, it was discovered that stem cell antigen (Sca-1)–positive 
cells are able to reconstitute mammary glands but since this antigen is not detectable in 
human tissues, other MaSC markers need to be found and used in place of Sca-1 and as 
yet, there is no conclusive marker for mammary stem cell, with several markers 
suggested by different research groups. Several studies have described bi-potent  
progenitors cells in normal adult mammary tissue based on the sorting with epithelial 
specific antigen (ESA), mucin-1 (MUC-1) and α6-integrin with cells that are MUC-1-
/weak/ESA+/CD10+/weak/α6-integrin+ were able to generate clones containing cells 
of both lineages (Stingl et al. 1998; Stingl et al. 2001). Gudjonsson and team reported 
that cells that give rise to mixed colonies comprising both luminal and myoepithelial 
cells expressed CK19 and are CK14+CK18+ (Gudjonsson et al. 2002a) while Dontu et al 
and Bocker et al in 2 separate research articles report that CK5-positive cells define the 
stem cell population (Bocker et al. 2002; Dontu et al. 2003a). Mammary stem/ 
progenitor cells were also found enriched in oestrogen receptor (ER)-positive 
populations (Gudjonsson et al. 2002a; Dontu et al. 2003b; Clarke et al. 2005).  
 
Using flow cytometric cell sorting based on exclusion of the fluorescent DNA dye 
Hoechst 33342, a method that has crossed over from the haemopoietic system, 3 




different groups have a range between 0.2% (Alvi et al. 2003; Clayton et al. 2004) and 
1% (Dontu et al. 2003a), and as high as 5% (Clarke et al. 2003; Clarke et al. 2005) of 
side-population (SP) being present in human breast tissue and that only cells within this 
SP can produce colonies with both myoepithelial and luminal epithelial cell types 
(Dontu et al. 2003a; Clayton et al. 2004; Clarke et al. 2005). Drawing results from these 
murine models, it was then found that SP cells give rise to all three mammary epithelial 
cell lineages when transplanted into cleared fat pads (Welm et al. 2002; Alvi et al. 2003) 
which further support the hypothesis that the SP is enriched in mammary epithelial stem 
cells. Finally, human SP cells seem to form much larger branching colonies in matrigel 
compared to non-SP (NSP) (Clarke et al. 2005) and they are highly enriched for the 
ability to grow in non-adherent conditions as spheroids, another feature of 
stem/progenitor cells (Dontu et al. 2003a), mentioned  in detail below. 
 
In addition to surface markers and proteins, another less biased approach is the isolation 
and propagation of the mammary stem and progenitor cell using a suspension medium; 
this is a method extrapolated from the field of neural stem cells which are routinely 
grown as neurospheres (Campos 2004; Suzuki et al. 2004). For this method of isolation 
through culture, it was found that human mammary epithelial cells form spherical 
colonies at clonal densities in the serum-free medium, exhibiting a property of stem 
cells (Dontu et al. 2003a; Dontu et al. 2004; Dontu and Wicha 2005). Dontu et al further 
establish that only SP and not NSP are able to form the spherical colonies, also known 
as mammospheres (Dontu et al. 2003a). Extending the use of mammospheres’ culture to 
identify MaSC, the latter were found enriched in Lin-/CD24+/CD29hi or Lin-
/CD24+/CD49f++ population (Shackleton et al. 2006; Stingl et al. 2006a) and that the 
cells that formed the mammospheres are capable of self-renewing and they differentiate 




into terminal ductal lobular units (TDLU) when placed into matrigel-coated plates 
(Dontu et al. 2003a). Shackleton and team also went on to quantify the frequency of 
mouse MaSC which was approximately 0.1% of the cells in freshly prepared cell 
suspension from mammary tissue (Shackleton et al. 2006). They also showed through 
flow cytometry that mammary gland of both mice and human contain a parallel 
distribution of basal and luminal subpopulations and that in both species, the most 
primitive cell types identified thus far are those that copurify with basal cells that 
express the highest level of CD49f and lower levels of CD24 (for mice) or EPCAM (for 
humans) (Stingl et al. 2006b).  
 
The observation that three types of colonies (luminal only, myoepithelial only and both 
cell types) can be formed from single mammary epithelial cells when they were plated 
at low densities (Stingl et al. 1998; Gudjonsson et al. 2002b) indicating that there are 
the luminal restricted and the myoepithelial restricted progenitors and the stem cells that 
are bipotent (Anderson and Clarke 2004). 
 
It was found that MaSC reach senescence after 40 to 50 self-renewing stem cell 
divisions (Kordon and Smith 1998). They exhibit ductal growth senescence on serial 
transplantation after six generations (Young et al. 1971; Smith et al. 2002). 
 
Stem cells are found in the mammary gland during all stages of development and very 
interestingly, there even exists a population of stem cells which are parity-induced 
(Wagner et al. 2002). Using transgenic whey acidic protein-driven Cre and Rosa 26-fl-
LacZ mice, Smith and colleagues demonstrated the presence of a new mammary 
epithelial cell population which originates from the differentiating cells during 




pregnancy and that 5-10% of this parity-induced epithelium survives post-lactational 
involution after the first pregnancy. With successive pregnancies, the population 
percentage increases, reaching 60% of the total epithelium in multiparous females 
(Wagner et al. 2002; Henry et al. 2004; Boulanger et al. 2005). These cells served as 
progenitors and differentiate into both ductal and lobuloalveolar cells upon serial 
transplantation. They, similar to the known MaSC, proliferated to produce both luminal 
and myoepithelial cells in limiting dilution transplantation (Boulanger et al. 2005). This 
unique population of cells is implicated as a crucial factor in the observed risks of 
parous females in contracting breast cancers.  
 
1.4.1.4 Association with Tumorigenesis 
As stem cells persist in the mammary gland throughout reproductive life, they have the 
potential to accumulate genetic damage and to transmit it to their progeny and hence are 
regarded as prime targets for oncogenic transformation (Anderson and Clarke 2004). 
This is supported by increasing evidence of the presence of cancer stem cell in 
malignancies of various tissues (Reya et al. 2001; Smith 2002; Dontu et al. 2003b; 
Smalley and Ashworth 2003; Al-Hajj and Clarke 2004; Waterworth 2004). This 
together with the observation that majority of the human breast tumours arose in the 
TDLU and that they are luminal cells (Wellings et al. 1975; Taylor-Papadimitriou et al. 
1986; Taylor-Papadimitriou et al. 1989) brings about a theory that breast cancer may be 
at least in part, a stem cell disease.  
 
Nestin is expressed on the regenerative component of the mammary gland. Interestingly, 
breast tumours with a basal epithelial phenotype, which is highly aggressive and poorly 
differentiated, also express nestin in all of the sixteen tumours tested by Li et al. (Li et 




al. 2007). Global transcriptional profiling have found that the tumours within the basal 
breast cancer subtype are particularly associated with mutations in BRCA1 (van 't Veer 
et al. 2002) and Li et al further showed that nestin expression is well correlated with 
BRCA1 associated cancer, which are classified as a basal breast cancer (Li et al. 2007). 
This suggests that at least one cancer subtype, the basal breast cancer display a 
progenitor-like phenotype (Li et al. 2007), once again implicating MaSC as an 
aetiological factor in breast cancer.  
 
Malignant mammary epithelial cells are unable to differentiate to the two mature cell 
types in culture (Rudland et al. 1997), which can possibly be explained by two different 
theories. In the first theory, there are two different types of epithelial stem cells in 
normal mammary glands, one which can differentiate to benign lesions and the other 
which give rise to malignant lesions. This was illustrated with the immunocytochemical 
staining pattern of the epithelial cells within the normal human mammary gland where 
there was a differential expression of CK19, with the malignant cells showing an 
increased expression (Taylor-Papadimitriou et al. 1983; Taylor-Papadimitriou and Lane 
1987). An alternative theory states that the ability of the epithelial stem cells  to 
differentiate is impaired when they become malignant (Rudland et al. 1997), which is 
supported by evidence obtained from experimental carcinomas in rats and observations 
made on human carcinomas. In the rodent studies, the benign tumours which contain 
predominantly only the one major epithelial cell type can develop into malignant 
metasising tumours with serial transplantation (Rudland 1987) whereas in the human, 
transfection of rat epithelial stem cells lines with cells of malignant origin will induce 
specifically the malignant cell types and not differentiate into myoepithelial-like or 
alveolar-like cells (Davies et al. 1993).  




The above evidences strongly suggest the involvement of MaSC in tumourigenesis and 
therefore, the study of mechanism of self-renewal, the malignant transformation as well 
as the potential cell lineages that can arise from MaSC are likely to provide new 
insights into the carcinogenic process. The realisation that proper cellular differentiation 
is a powerful inhibitor of cancer initiation provides a strong rationale for pursuing the 
identification of the stem cells susceptible to carcinogenesis and of the genes that 
control this process. This would allow us to target key pathways to either induce 
differentiation or apoptosis, improving the current state of the art treatment regimen 
(Kalirai and Clarke 2006). In addition, this approach may allow the development of new 
tools for developing rational strategies for breast cancer prevention (Russo et al. 2005; 
Cariati and Purushotham 2008).  
 
1.4.2 Haemopoietic Stem and Progenitor Cells 
Haemopoietic stem cells is the first stem cell source used for transplantation purposes 
and has been in use over 30 years (Clark et al. 2003). HSC transplantation, after 
myeloablative chemotherapy in both autologous and allogeneic settings have become an 
established therapeutic option in the management of haematological malignancies, 
thalassaemia, sickle cell disease and aplastic anaemia (Vassiliou et al. 2001; Tabbara et 
al. 2002). In fact in recent years, research on HSC suggests that their therapeutic uses 
extend beyond haematological diseases. There have been many studies that illustrate the 
multi-lineage stem cell plasticity of HSC as they differentiate and contribute to the liver, 
(Lagasse et al. 2000; Forbes et al. 2002), central nervous system (Mezey et al. 2000), 
endothelia (Grant et al. 2002) and skeletal muscle (Bittner et al. 1999). All these 
collectively suggest the theoretical potential for HSC to treat many diseases. While ex 
vivo expansion of HSC may allow their sources to be viable sources of stem cells for 




transplantation purposes and replacement therapies, it is necessary to understand that 
much is still unknown about HSC and hence, the interest in HSC, particularly its 
plasticity has to continue and this interest is very likely to be sustained.  
 
Haemopoietic stem cells (HSC) are multipotent precursors that have self-renewal 
capacity and the ability to regenerate all the different cell types that comprise the blood 
forming system which include erythrocytes, neutrophils, monocytes, macrophages, 
platelets, T lymphocytes, B lymphocytes, natural killer T cells, dendritic cells and 
others (Bonnet 2002; McCulloch and Till 2005; Broxmeyer et al. 2006). Limiting 
dilutions analysis of total bone marrow preparations allowed quantitative estimation of 
HSC frequencies ranging from 1 in 10,000  to 1 in 100,000 (Harrison 1980; Szilvassy et 
al. 1990; Harrison et al. 1993). The primitive HSC is by definition, both self-renewing 
and capable of long-term repopulation (LTR) and resides at the base of progenitor cell 
development (Lord 1997). It must have the ability to give rise to all lineages of mature 
blood cells and offer radioprotection to a lethally irradiated host (Nolta and Kohn 1997; 
Lagasse et al. 2000).  
 
Haemopoietic progenitor cells, on the other hand, have more limited capacity for self-
renewal than stem cells, and they are more restricted in their capacity to give rise to 
multiple cell types, with the hierarchy as shown in Fig. 1-2. However, more is known 
about them than HSC. This is in part because the stem cells are rarer in frequency than 
the progenitors, and assays for progenitor cells performed in vitro, are easier to do than 
assays for engrafting stem cells, which are done in vivo (Broxmeyer et al. 2006). 
Progenitors are ranked as those that are immature with enhanced proliferative capacity 
and  those with that are more mature, with decreased proliferative capacity, and those 




that are mature, with decreased proliferative and more limited and restricted 
differentiation capability (Broxmeyer et al. 2006). It is believed that the immature 
subsets of progenitors are responsive to stimulation by combinations of growth factors 
(Shaheen and Broxmeyer 2005). Thus multipotential progenitor cells (termed colony-
forming unit-granulocyte, erythrocytes, macrophage, megakaryocytes, CFU-GEMM or 
CFU-Mix) are denoted by the colonies of mixed lineage blood cells they give rise to in 
semisolid culture medium when the cells are stimulated in vitro, with combinations of 
cytokines such as erythropoietin (Epo), stem cell factor (SCF), granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), in the absence or 
presence of thrombopoietin (TPO) (Broxmeyer et al. 2006).  





Figure 1-2 Scheme of Haemopoiesis. Adapted from (Lord 1997). 
 
1.4.2.1 Sources of Haemopoietic Stem/ Progenitor Cells 
Both cord blood and bone marrow are well-established sources of haemopoietic stem/ 
progenitor cells. Haematopoietic progenitor cells in cord blood are increased in 
frequency compared with those in bone marrow (Broxmeyer et al. 1989) and are 
enhanced in proliferative capacity, generation of progeny and also replating capacity in 
vitro (Broxmeyer et al. 1989; Carow et al. 1991; Broxmeyer et al. 1992; Cardoso et al. 
1993; Lansdorp et al. 1993; Lu et al. 1993). Transplantation of HSC forms the basis of 
consolidation therapy in cancer treatments and they are used to cure or ameliorate a 
number of haematologic and genetic disorders (Shizuru et al. 2005; Steward and Jarisch 
2005). As such, these cells are widely harvested from cord blood (Broxmeyer 2004; 
Broxmeyer 2005) and bone marrow for therapeutic purposes.  
 




1.4.2.2 Isolation and Purification of Haemopoietic Stem/ Progenitor 
Cells 
The rarity of the primitive HSC results in the difficulty in their isolation and 
purification. The most commonly used technique for separating early progenitor cells 
today is based on the use of monoclonal antibodies. Once labelled with antibody, cells 
can be separated using solid phase immunological methods of immunomagnetic 
particles or flow cytometry (Lord 1997). One such antigen which identifies HSC is 
CD34 (Link et al. 1996), which make up approximately 1% of all human bone marrow 
cells (Hao et al. 1995). Subsequently, by assessing the coexpression with other cell 
surface markers, it is possible to obtain cell fractions that are more highly enriched for 
primitive cell types (Craig et al. 1993; Huang and Terstappen 1994; Hao et al. 1995). It 
was found that lin-/CD34+ subpopulation have defined more primitive precursors with 
haemopoietic repopulating activity that expresses combinations of the CD59 surface 
antigen related to Stem-cell antigen (Sca-1), the vascular endothelial growth factor 
receptor-2 (VEGFR2) and low levels of c-kit (CD117), Thy-1 (CD90) and CD38 (Baum 
et al. 1992; Gunji et al. 1993; Civin et al. 1996; Hill et al. 1996; Kawashima et al. 1996; 
Larochelle et al. 1996; Ziegler et al. 1999).  It was only in 1997 when CD133 become 
appreciated as another important HSC marker (Yin et al. 1997; de Wynter et al. 1998; 
Gallacher et al. 2000; Lang et al. 2004; Hess et al. 2006).  CD133, the human 
homologue of mouse Prominin-1 (Shmelkov et al. 2005) was first identified as a 
selective human HSC surface molecule. Selection for CD133+ haemopoietic precursors 
yields more than 90% CD34+ cells while containing all the human repopulating activity 
(Hawley et al. 2006). The lin-/ CD34+ or CD34+/ Thy-1+/ Lin- or CD34+/ CD38- or 
CD133+ purified cell types were capable of engraftment into SCID mice (Chen et al. 
1994; Murray et al. 1995; Kerre et al. 2001; Handgretinger et al. 2003).  





Besides the use of cell surface markers, rhodamine 123 which preferentially 
accumulated in active mitochondria) and Hoechst 33342 (a bis-benzimidazole that 
binds to the adenine -thymine-rich regions of the minor groove of DNA) are two 
fluorescent dyes that have been routinely used to characterize haemopoietic precursor 
populations (Visser et al. 1981; Bertoncello et al. 1985; McAlister et al. 1990; Wolf et 
al. 1993; Leemhuis et al. 1996).  Goodell et al described a method that simultaneously 
monitors the low fluorescence intensity of Hoechst 33342 staining at 450nm and 
at >650nm after ultraviolet excitation, which identifies a rare subpopulation referred to 
as side-population (SP) cells enriched with HSC (Goodell et al. 1996). First used, on 
mouse bone marrow cells, it was found to contain the majority of long-term 
haemopoietic repopulating activity (Goodell et al. 1996). Since then, the SP assay has 
been applied to human haemopoietic tissues (Goodell et al. 1997; Storms et al. 2000; 
Uchida et al. 2001; Preffer et al. 2002; Eaker et al. 2004; Naylor et al. 2005) and this list 
is not comprehensive.  
 
1.5 Discussion 
MaSC have been isolated in both human and murine models (Dontu et al. 2003a; 
Shackleton et al. 2006). They have been suggested as the likely targets for malignant 
transformation leading to breast cancer which remains the most common malignancy 
among females worldwide. This is due to common properties of longevity and the self-
renewal property with tumorigenic cells (Dontu et al. 2003b; Dontu et al. 2005; Ponti et 
al. 2005). Research groups worldwide are attempting to identify the cell type most 
susceptible to malignancy (Dontu et al. 2005; Sleeman et al. 2006). The identification 
of susceptible cell types may allow the control of this life-threatening disease through 




primary prevention. Identification of mammary stem cell markers will also help us in 
understanding normal development of the mammary gland, and provide tools to 
characterize the role of stem cells in breast cancer.  To date, the only source of human 
MaSC were tissues derived from reduction mammoplasties (Dontu et al. 2003a; 
Shackleton et al. 2006; Stingl et al. 2006b). Isolation of mammary stem/ progenitor 
cells from mammary tissue requires a complicated isolation technique with long 
digestion times by various enzymes. This is due to the fact that the composition of the 
mammary gland contains adipocytes, collagen-impregnated stroma surrounding ductal 
epithelium, basement membrane, and tightly interacting epithelial cells, which does not 
make it an ideal tissue to produce single cell suspension efficiently. In order to do so, 
long digestive procedures are required which  may potentially destroy and/ or mask cell 
surface epitopes important for isolation and identification of these cells (Wagner et al. 
2002; Welm et al. 2003). Therefore, there is a demand for other sources of MaSC which 
are more easily available and obtained in a less invasive manner and do not require 
cumbersome procedures to derive single cell suspension for subsequent work. 
 
The work revolving around HBM thus far has mainly been focusing on the nutritive 
value for the infant. Immune and epithelial cells are the only cell types reported to exist 
in HBM [discussed in detail in Section 1.3.6]. Until now, there has been no literature 
reporting the presence of mammary stem/ progenitor cells in HBM, although there was 
a commentary highlighting the possibility and that it could be an unappreciated source 
of stem cells (McGregor and Rogo 2006). Relating to other systems with epithelial cell 
lining, there have been some studies documenting the presence of the epithelial stem 
cell in the luminal discharges due to the proximity of the stem cell niche to their luminal 
cavities.  Most recently, mesenchymal progenitor cell types have been isolated through 




the collection of human menstrual blood (Hida et al. 2008; Musina et al. 2008), which 
has been postulated to derive from the stromal regions of the endometrial glands. 
Similarly, it has been proposed that the epithelial stem cells reside in the niche at the 
base of the glands in the endometrium (Gargett 2007), and shown to be present just 
beneath the luminal epithelium and in the endometrial-myometrial junction (Chan and 
Gargett 2006; Cervello et al. 2007). From urine, rare stem/ progenitor cell types from 
the epithelial, urothelial and smooth muscle lineage have been identified at a clonal 
level, with the capacity for self-renewal and multi-lineage differentiation (Zhang et al. 
2008). In the gastro-intestinal system, stem cells have been localized to the basal crypts 
(Marshman et al. 2002; Bjerknes and Cheng 2006), although there have been no reports 
of these epithelial stem cells being shed into the gastrointestinal tract. Nonetheless, 
extrapolating these reports to a tissue of common lineage, they suggest the plausibility 
of stem/ progenitor cells being shed into HBM either by means of sloughing or active 
shedding into the lumen for yet unknown purposes. 
 
I aimed to identify and isolate putative stem/ progenitor cells which have shed into 
HBM during lactation, although whether this shedding serves a specific functional 
purpose sets the platform for another research question. Pursuing the question of 
whether stem cells exist in HBM would also allow the complete identification of the 
components in HBM which might elucidate other potential powerful biologic benefits 
of human lactation (McGregor and Rogo 2006). From Section 1.3.6, it has been 
established that majority of the cellular component of HBM are leukocytes (early days 
postpartum). As HSC share the common markers of CD133 and SP with MaSC, the 
possibility that these cells may be true HSC needs to be explored, although the 




biological rationale for such a finding is still an unknown entity. Hence, I have devoted 




1. Adult stem/ progenitor cells are present in HBM. 
2. These stem cells are able to demonstrate multi-lineage differentiation capacities.  
 
1.5.2 Significance of Study 
 
This attempt to isolate stem cells from human milk may have various implications 
relating to:  
 
1. Breast tissue engineering - This will be of value to patients who have had 
mastectomies or traumatic injuries, where autologous stored stem cells could be used as 
a tissue engineering cellular source.  
 
2. Elucidating mechanisms for mutagenesis and oncogenesis in breast cancer - It has 
recently been shown that cancers, including those in the breast (Al-Hajj et al. 2003), 
arise from transformed stem cells which accounted for the heterogeneity of solid 
tumours, and their resistance to chemotherapy. Thus, the availability of MaSC will 
allow studies of mutagenesis and other events related to carcinogenesis to be studied in 
detail, and possible therapeutic agents to be developed. 
 




3. Biology of lactation - Until now, it is unclear how the process of lactation is initiated 
and maintained at the cellular and glandular level. Identification of MaSC may allow 
the dissection of cellular response to changing hormonal signals which occurs during 
pregnancy and lactation. This may have implications in identifying causes for various 
lactational problems, an issue with dire consequences particularly in developing 
countries (Mepham 1983). 
 
4. Dissecting microchimerism of maternal cells in breastfed infant - If mammary and/ or 
haemopoietic stem cells are actively passed out to the infant, we could be potentially 
studying the effects of these cells in the breastfed infant which might explain in part, the 
long term benefits HBM have over formula, and certainly open up a new field of study 
worth pursuing. 
 
5.   Providing a non-invasive novel source of HSC - This potentially allows the banking 
of HSC from all lactating females for their future use, given the known fact that HSC 
transplantation has been applied to several clinical settings where they have been 














































2 Materials and Methods 
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 2.1 Samples 
2.1.1 Research Ethics Board Approval 
Ethics approval was obtained from the Domain Specific Review Board (DSRB) of the 
National Healthcare Group (NHG) for collection of human samples (DSRB Ref: 
D/04/206). All participants gave written informed consent for the donation of samples 
for research purposes. 
 
2.1.2 Cells from Human Breast Milk 
Informed written consent were obtained from healthy lactating women who had 
delivered within a year and the breast milk samples collected in sterile containers. A 
total of forty-one breastfeeding women (duration of lactation – 1 to 12months) were 
recruited to participate in the study. All samples were collected and processed within 
four hours of expression. 
 
Whole cell population was isolated from human breast milk by centrifugation. The 
expressed human breast milk was spun down at 400g for 10mins. The cell pellet was 
then washed twice with RPMI medium before use for subsequent experiments. 
 
 
2.1.3 Umbilical Cord and Peripheral Blood Cells 
 
Umbilical cord blood was collected at normal deliveries of full term pregnancies (n=2) 
while peripheral blood were collected from a volunteer (n=1). The umbilical cord blood 
as well as the peripheral blood was diluted 4-fold with PBS (137mM NaCl, 10mM 
Phosphate, 2.7mM KCI, pH 7.4) with 2mM EDTA (Gibco). Every 35mL of diluted 
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blood was carefully layered over 15mL of Ficoll 1077 (Invitrogen, California, USA) 
and centrifuged at 400g for 35mins in a swinging-bucket rotor with brakes off. The top 
layer of plasma was removed before collecting the mononuclear cells at the interphase 
with a 22 Gauge needle attached to a 3mL syringe. The cells were washed twice with 
PBS/ 2 mM EDTA before being used as controls; cells from cord blood were used for 
methylcellulose assays and cells from peripheral blood for reverse transcription 
polymerase chain reaction; these are discussed more in detail in Sections 2.2.6 and 2.3. 
 
2.1.4 Cells from Fetal Brain 
Human fetal brain tissue samples from medically aborted fetuses at 15-18weeks of 
gestation were collected (n=5). The hippocampus, subventricular zone, thalamus, brain 
stem, cerebellum, spinal cord, anterior and posterior cerebra were teased out and 
mechanically minced with a scalpel. The minced tissues were then dissociated 
enzymatically with 0.25% trypsin for 15mins at 37°C. Thereafter, an equal volume of 
40mg/ mL of bovine serum albumin (BSA) suspended in Earles’ balanced salt solution 
(Invitrogen, Carlsbad, CA) were added to inactivate the trypsin. The cell suspension is 
then filtered through 70µm filters (BD Biosciences, Franklin Lakes, NJ) and washed 
twice with PBS (137mM NaCl, 10mM Phosphate, 2.7mM KCI, pH 7.4) before 
counting.  Viability of cells was determined with 3% acetic acid with methylene blue 
(StemCell Tech, Canada). Cells isolated from fetal brain were used for reverse 
transcription polymerase chain reaction and as one of the positive controls for spherical 
cultures. 
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2.1.5 Fetal Mesenchymal Stem Cells 
Mesenchymal stem cells were derived by flushing the bone marrow of medically 
aborted fetuses at 18weeks (n=1). This is done using a 22 Gauge needle attached to a 
syringe. The suspension is then filtered through 70µm nylon filter (BD Falcon, MA, 
USA) to get single cells. These fetal mesenchymal stem cells were used for reverse 
transcription polymerase chain reaction in Section 3.3.2. 
 
2.1.6 Breast Adenocarcinoma Cell Line, MCF-7 
MCF-7, a breast adenocarcinoma cell line was obtained from American Tissues Culture 
(ATCC, HTB - 22). This cell line is derived from a 69 year old Caucasian lady. This 
cell line is chosen as a suitable control for my work as it retains several characteristics 
of differentiated mammary epithelium. In addition, it has been reported to contain a 
group of cells known as side-population which possesses the ability to exclude Hoechst 




2.2 Cell Culture 
2.2.1 Epithelial Cell Culture  
The cellular fraction of breast milk was suspended and cultured in RPMI (Roswell Park 
Medical Institute) supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(Gibco), 2mM L-glutamine, 4µg/ mL insulin (Sigma-Aldrich, Mossouri, USA), 0.5µg/ 
mL hydrocortisone (Sigma-Aldrich), 20ng/ mL epidermal growth factor (BD 
Bioscience, California, USA), 60ng/mL cholera toxin (Sigma-Aldrich) and 0.1mg/ mL 
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of penicillin/streptomycin/fungizone (Biowhittaker, Verviers, Belgium). The cells were 
cultured for 7 to 50 days at a density of 105 cells/ cm2 until confluence. Cells cultured 
for immunocytochemistry were cultured on 13mm diameter circular coverslips in 24-
well tissue culture plates (Sarstedt, Numbrecht, Germany) at 37°C with 5% CO2 and 
95% relative humidity. 
 
Epithelial medium placed onto an established culture of lactocytes for 72hours were 
collected and passed through 0.2µm filters to remove cells. They were then kept in 




2.2.2 Mammosphere Culture  
To attempt to grow MaSC from cells directly isolated from HBM, cells from HBM 
were also grown in a serum-free mammary epithelial growth medium (Cambrex, New 
Jersey, United States), supplemented with B27 (Invitrogen), 20ng/ mL epidermal 
growth factor (Sigma-Aldrich), 20ng/ mL basic fibroblast growth factor (BD 
Biosciences) and 4µg/ mL heparin (Sigma-Aldrich). Cells were placed on ultra-low 
attachment plates at various densities of 1, 100, 1,000 and 3,000 cells per well of a 96-
well plate to establish their ability to grow clonally, in a manner MaSC from human 
mammary tissue were previously cultured (Dontu et al. 2003a). These cultures are then 
observed weekly after 2 weeks, up to 5 weeks for mammospheres formation. 
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2.2.2.1 Optimisation of Mammosphere Media 
Cells intended for growth into mammopsheres were first plated singly into each well of 
a 96-well plate. I next proceeded to plate the cells into low adherence 96-well plates at 
both low plating density of 3x103cells/ cm2 and high plating density of 9x103cells/ cm2.  
 
Further to this, I added in conditioned medium, derived as described in Section 2.2.1 in 
varying concentrations as shown in Table 2-1. Varying concentrations of epidermal 
growth factor (EGF) (Sigma-Alrich), basic fibroblast growth factor (bFGF) (Sigma-
Aldrich) and fetal bovine serum (FBS), as tabulated in Table 2-1, were also used in the 
optimisation of mammosphere medium for culture.  
 
Substances added into mammosphere medium   
Fetal Bovine Serum (%) 1 3 5 10 20 
Epidermal Growth Factor (ng/ ml) 20 40 60 80 100 
Basic Fibroblastic Growth Factor (ng/ ml) 20 40 60 80 100 
Conditioned Medium (%) 1 5 20 50 80 
 
Table 2-1: Factors for optimisation of mammosphere medium.  
 
 
2.2.2.2 Coating of Substratum  
2.2.2.2.1 MatrigelTM coating 
MatrigelTM Matrix (BD Biosciences) is a solubilized basement membrane preparation 
extracted from sarcoma, a tumor rich in extracellular matrix. At room temperature, it 
produces biologically active matrix material resembling the mammalian cellular base 
and is known to be especially suited for culture of epithelial cells. 
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MatrigelTM is allowed to defrost slowly on ice. 20µl of matrigel was aliquoted and 
spread with a pipette tip into each well of a 96-well plate (Nunc, Roskilde, Denmark). 
The excess was aspirated away and the plates left to incubate on ice for 30mins 
followed by incubation at 37°C for 30mins to ensure setting of the gel. Thereafter, 
200µl of medium was added into each well. 
 
2.2.2.2.2 Collagen coating 
Twenty microliters of 1mg/ mL collagen solution (Sigma-Aldrich) was placed onto 
each well of a 96-well plate and spread using a pipette tip. The plate was left at room 
temperature to air-dry after aspirating away the excess collagen. 200µL of medium was 
then added into each well and the plate left at 37°C for an hour, before use. 
 
2.2.2.2.3 Gelatin coating 
 
Dissolve 12mg of gelatin (Sigma-Aldrich) in 12mL of sterile water.  The 0.1% gelatin 
solution was sterile-filtered before being loaded onto each well of a 96-well plate. The 
plate was then left in the incubator at 37°C for an hour, before the excess gelatin 
solution was removed. 200µL of medium was then added into each well. 
 
2.2.2.2.4 Fibronectin coating 
The recommended use of fibronectin (Sigma-Aldrich) is at a concentration of 1.5µg/ 
cm2 and each well of a 96-well plate has an area of 0.32cm2. Therefore, 8µL of 0.1% 
fibronectin was loaded onto each well. After coating the wells, the plate was left in the 
incubator at 37°C for an hour before 200µL of mammopshere medium was added into 
each well. 
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2.2.3 Neurosphere Culture 
For neurospheres initiating assays, cells isolated from the fetal brain were plated at a 
concentration of 3x104 cells per mL of neurosphere medium which is 1:1 Dulbecco's 
Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/ F-12) (Gibco) supplemented 
with 1% N2 supplement (Gibco) and 1x antibiotic/antimycotic (Invitrogen) for  four 
weeks.   
 
At the end of four weeks, the neurospheres were then dissociated using TrypIE 
(Invitrogen) and mechanical dissociation. The single cells are then cultured with 
differentiation medium, DMEM/F-12 with 1% N2 supplement, 1% FBS and 1x 
antibiotic/antimycotic on poly-L-ornithine–coated coverslips for one week before the 
coverslips were washed with phosphate buffered saline (PBS) and fixed with 1:1 
methanol/ acetone for 5mins at -20°C. These were then used for immunocytochemistry. 
 
2.2.3.1 Poly-L-ornithine Coating of Coverslips 
Each coverslip was placed into a well of a 24-well plate and washed with 70% ethanol 
and left to dry. Thereafter, each glass coverslip was covered with 200µL of 0.1mg/ ml 
poly-L-ornithine solution for two hours at room temperature. The solution was then 
aspirated away and wells washed with distilled water twice. The 24-well plates were 
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2.2.4 Fetal Mesenchymal Stem Cell Culture 
These cells which were flushed out from bone marrow were cultured in DMEM 
(Dulbecco's Modified Eagle's Medium) (Gibco), supplemented with 10% FBS (Sigma-
Aldrich), 1% L-glutamine (Gibco) and 1x penicillin/ streptomycin (Gibco) in T75 flasks, 
at a cell density of 106 cells per mL of culture media. The non-adherent cells were 
removed after three days and new medium added. The adherent cells were subcultured 
every two to three days when confluent, at a cell density of 104 cells per cm2 in T75 
flasks. Adequate cell numbers were cultured and then harvested for RNA extraction, to 
be used as a positive control in Section 3.3.2. 
 
 
2.2.5 Culture of Cell Line, MCF-7 
These cells were cultured in DMEM (Dulbecco's Modified Eagle's Medium) (Gibco), 
supplemented with 10% FBS (Sigma-Aldrich), 1% L-glutamine (Gibco) and 1x 
Penicillin/ Streptomycin (Gibco) in T75 flasks. The cells were subcultured 1:3 every 
four to five days when confluent. MCF-7 cells were used as both negative [in Section 
3.3.1, 3.3.2 and 3.3.3] and positive controls [in Section 3.3.4 and 5.4.1.1.2]. 
 
2.2.6 Methylcellulose Culture 
Cells derived from cord blood and HBM were placed in HSC-CFU lite with Epo 
(Miltenyi) at 1,000 to 3,000 cells per mL as per manufacturer’s instructions. 
Specifically, individual specimens were mixed with 3 mL of methylcellulose containing 
bovine serum, stem cell factor, granulocyte-macrophage colony-stimulating factor, 
interleukins-3 and 6, erythropoietin, and plated in 35-mm tissue culture dishes in 
duplicates for two weeks and then observed for colonies formation. 
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2.3 Reverse Transcription Polymerase Chain Reaction 
2.3.1 RNA Extraction 
Whole RNA was extracted from cells using RNAeasy columns (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. The isolated DNAse-treated 
RNA was quantified with a spectrophotometer (Beckman, California, USA).  
 
2.3.2 Reverse Transcription 
One microgram of total RNA was reverse-transcribed using oligo-dT primers (Proligo, 
Sigma-Aldrich), RNase inhibitor (Roche, Basel, Switzerland) and the Sensiscript kit 
(Qiagen) at 25°C for 15mins, 42°C for 60mins and 72°C for 15mins. Negative controls, 
without reverse transcriptase, were performed for each RNA sample to ensure absence 
of DNA contamination. 
 
2.3.3 Polymerase Chain Reaction 
PCR cycling conditions were as follows: 94°C for 120s followed by 30-40 cycles of 
denaturation (94°C for 15-30s), annealing (55-68°C for 15-30s) and extension (72°C for 
60s) and a final extension at 72°C for 4mins. The PCR products were electrophoresed 
in 1.2% agarose gels stained with ethidium bromide in TE electrophoresis buffer. The 
PCR bands were visualised using a UV illuminator. RT without reverse transcriptase 
and PCR reaction with water in place of cDNA were negative controls to exclude DNA 
contamination. Commercial genomic DNA (Applied Biosystems, California, USA) was 
used as a positive control. Primers used for PCR amplification were as shown in Table 
2-2. 




Primer           Sense 5’→3’                        Antisense 5’→3’              Size (bp) 
 
GAPDH aaggactcatgaccacagtccatg ttgatggtacatgacaaggtgcgg 673  
NES  ggtcagttcctgaagttcactcag cctagtactatcgggattcagctg 343  
CK5  cgacaaggtgcggttcctg  gcagattggcgcactg  683 
CK14  gatgacttccgcaccaagtatgag tcaatctccaggttctgcatggtg 440 
CK18  agaaatctgaaggccagcttggag taccctgcttctgctggcttaatg 372 
CD34  gacactgtggacttggtcaccag gaggaggaagccatggagatcag 310 
CD133  ccaagttctacctcatgtttgg  accaacagggagattgcaaagc 480 
ON  atttgatgatggtgcagaggaa ggtggttctggcagggattt  65 
ALP  caggctggagatggacaagttc ggacctgggcattggtgtt  68 
OP  cctgccagcaaccgaagtt  cactatcacctcggccatca  67 
MSI  gtgtgaggtgcttaacctatcagc acagatgtggagagaagagacacc  359 
NFM  cttcagccagtcctcgtccc  tcctccaggtggtccgagtc  312 
 




2.4.1 Slides and Controls 
Cells were either cytospun onto glass slides at a density of 2-5x104 cells per slide or 
grown on glass coverslips in 24-well plates till sub-confluency.  
 
2.4.1.1  Controls for Immunocytochemistry 
Controls for immunocytochemistry include an external negative cell type known not to 
express the antigen, an external positive cell type known to express the antigen and an 
internal negative control, where the incubation with primary antibody is omitted. 
 
2.4.1.2 Controls for Flow Cytometry 
Isotype controls were used for the directly conjugated antibody. Incubation with the 
secondary antibody alone was used as control for those antigens detected via indirect 
flow cytometry. An external cell type known to express the antigen-in-study and an 
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A list of antibodies and concentrations used are provided in Table 2-3. Prior to staining, 
samples were rinsed with PBS and fixed with ice-cold 1:1 acetone-methanol for 10min. 
After fixation, potential non-specific binding was blocked with 10% goat serum (Vector 
Laboratories, California, United States) and 3% Bovine Serum Albumin (Sigma-
Aldrich) in Tris-buffered saline for an hour at room temperature. For 
immunocytochemistry, all incubations were done in a humidified chamber. 
 
2.4.2.1 Immunocytochemistry by Alkaline Phosphatase/ Horse 
Radish Peroxidase 
 
Cells were incubated with primary antibody overnight at 4°C for 2hours at room 
temperature and washed thrice with PBST (phosphate- buffered saline with 0.5% 
Tween-20), 5mins per wash. Thereafter, they were incubated with biotinylated 
secondary antibody (1:100) for 30mins at room temperature, washed thrice with PBST 
before incubation with streptavidin alkaline phosphatase (Vector Laboratories) or 
streptavidin horseradish peroxidase (Dakocytomation, Glostrup, Denmark) (1:100) for 
30mins at room temperature. Freshly-prepared substrate was then added and incubated 
for 10mins in the dark for colour reaction to occur. Following this, the slides were 
rinsed with distilled water, followed by absolute ethanol. Depex mounting medium 
(Electron Microscopy Sciences, Pennsylvania, USA) was used to seal the coverslips. 
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2.4.2.2 Immunocytochemistry by Immunofluorescence 
Coverslips were incubated with primary antibody overnight at 4°C and followed by 
incubation with a fluorescent-labelled secondary antibody for 30mins at room 
temperature in the dark. The slides were then washed thrice with PBS and rinsed with 
distilled water. HardSet mounting medium with DAPI (Vector Laboratories) was added 
and the cells visualised and photographed with a Zeiss Axioplan 2 fluorescent 
microscope (Carl Zeiss, New York, USA). 
 
2.4.3 Flow Cytometry 
Flow cytometry is used to measure the numbers of particles or cells as they flow in a 
fluid stream singly through a detection point. The important feature of flow cytometric 
analysis is that measurements are made on individual particles or cells within the 
suspension and not as average values for the whole cell population. Fluorescein 
isothiocyanate (FITC) and phycoerythrin (PE) conjugated antibodies were used in the 
experiments. The emission maximum of fluorescein is 530nm and is visualised as green. 
PE has an emission maximum of 578nm and is visualised as red. Indirect flow 
cytometry was also performed with the use of anti-mouse IgG AlexaFluor 488 as the 
secondary antibody. The emission maximum of AlexaFluor 488 is similar to that of 
FITC.  
 
Cells were enzymatically lifted by incubation in trypsin for 5mins at 37°C, washed, and 
re-suspended in 100µL of blocking solution comprising 2mM EDTA in PBS 
supplemented with 10% FBS and 10% goat serum. After 30mins, antibody solution was 
added. Cells were washed twice in PBS by centrifugation at 400g for 10mins. 
Secondary labelling was carried out when unconjugated primary antibodies were used. 
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This process involved incubation of the cells with a 10% solution of secondary antibody 
in PBS for 20mins in the dark. Washing was then carried out to remove unbound labels. 
Cells were fixed by incubation in 4% buffered formaldehyde for 15mins, followed by 
washing in PBS. All stained samples were analysed with CyanTM ADP analyzer 
(Dakocytomation) within 72hrs and the results analysed with software, Summit 4.2. 
 
2.4.3.1 Extracellular Antigens 
For directly labelled antibodies, cells were suspended in 90µL of staining buffer and 
10µL of fluorochrome-labelled antibody added into the suspension. After an incubation 
of 20mins in the dark, the cells were washed twice with staining buffer (0.5% BSA/ 
2mM EDTA in PBS) by centrifugation at 400g for 5mins. The cells were re-suspended 
in 1 mL staining buffer for analysis.  
 
For the indirectly-labelled antibodies, cells have to undergo a blocking step by 
incubation with 5% bovine serum albumin (Sigma-Aldrich), 20% goat’s serum (Vector 
Laboratories) for 45mins at room temperature. Cells were then incubated with primary 
antibody diluted 20 fold with blocking solution. The cells were incubated for 30mins at 
room temperature before washing twice with staining buffer (similar to above). Cells 
were re-suspended and incubated for 15mins at room temperature in the dark in 488 
AlexaFluor-labelled goat anti-mouse antibody: blocking solution (1:200). The cells 
were then washed twice with staining buffer before re-suspension in 1 mL of staining 
buffer for analysis. 
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2.4.3.2 Intracellular Antigens 
Each cell sample was suspended in 1ml PBS, with 2ml 4% paraformaldehdye 
(Integrated Contracted Manufacturing Pte Ltd, Singapore, Singapore). The cell 
suspensions were washed with staining buffer and cells spun down by centrifugation. 
Cell pellets were incubated with 1mL of methanol for 10mins at -20°C before washing 
twice with staining buffer.  The cells were then incubated in 1mL of 0.5% Nonidet P40 
(Roche) in blocking solution (as mentioned above) for 45mins at room temperature to 
permeabilise the cells.  Primary antibody was added and incubated for 30mins at room 
temperature in the dark. Cell pellet were then washed twice with staining buffer and re-
suspended for incubation at room temperature in the dark with 488 AlexaFluor-labelled 
goat anti-mouse antibody diluted 200 fold with blocking solution. The cells were 
washed twice with the staining buffer before re-suspension in 1mL of staining buffer for 
analysis. 








Dilutions used Manufacturer 
ICC FACS 
     
CK5 Mouse 1:50 1:20 Sigma-Aldrich 
CK14 Rabbit 1:100 1:20 Chemicon 
CK18 Mouse 1:100 1:20 Chemicon 
CK19 Mouse 1:100 1:20 Dako 
Nestin Mouse 1:100 1:20 Chemicon 
Nestin Rabbit 1:200 NA Chemicon 
594 anti-Rabbit Goat 1:400 1:10 Molecular Probes 
488 Anti-Mouse Goat 1:400 1:10 Molecular Probes 
CD133 Mouse NA 1:10 R&D Systems 
CD34 Mouse NA 1:10 Chemicon 
RPE-CD24 Mouse NA 1:10 BD Pharmingen 
FITC-CD29 Mouse NA 1:10 Chemicon 
CD49f Mouse NA 1:10 Chemicon 
CDw338 Mouse NA 1:10 StemCell  
Stro-1 Mouse NA 1:25 Chemicon 
RPE-CD117 Mouse NA 1:10 Dako 
GFAP Rabbit 1:200 NA Sigma-Aldrich 
BIII Tubulin Mouse 1:100 NA Chemicon 
PDGFRα Rabbit 1:100 NA Upstate  
RPE- IgG2a Mouse NA 1:10 Dako 
FITC- IgG2b Mouse NA 1:10 Dako 
RPE- IgG1 Mouse NA 1:10 Dako 
FITC- IgG1 Mouse NA 1:10 Dako 
PE- IgG2b Mouse NA 1:10 Miltenyi 
 
Table 2-3: List of antibodies and concentrations. 
 
2.5 Cell Sorting 
2.5.1 CD133 tagged DynabeadsTM 
Mouse Antihuman-CD45 (BD Pharmingen, California, United States) and antihuman-
CD133 monoclonal antibody (Miltenyi, Gladbach, Germany) were tagged onto 
DynabeadsTM (Dynal AS, Invitrogen) and used to isolate CD45+ or CD133+ cells from 
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the whole cell population in HBM on separate occasions. DynabeadsTM are first washed 
with PBS/ 0.1% BSA. Using a magnet, the DynabeadsTM are then separated and 
supernatant discarded. Mouse antihuman CD133 or mouse antihuman CD45 were 
incubated with the DynabeadsTM are a concentration of 0.5µg per 107 DynabeadsTM for 
an hour at 4°C with gentle tilting and rotation. Thereafter, the tube is placed into a 
magnet for 2mins, to separate the DynabeadsTM from the supernatant which is 
discarded. The DynabeadsTM, now attached with relevant antibody are washed thrice 
with PBS/ 0.1% BSA before use. Isolation of the CD133+ or CD45+ cells from HBM 
were carried out based on manufacturer’s instructions. Purified mouse IgG (Chemicon) 
were bound to DynabeadsTM and used as negative controls.  
 
2.5.2 Fluorescence Activated Cell Sorting  
2.5.2.1 Hoechst Dye Exclusion 
Hoechst staining was performed as previously described (Storms et al. 2000). Cells 
from HBM, cord blood, and cell line, MCF-7 were sorted. Cells were then suspended in 
culture medium with Hoechst 33342 (Sigma-Aldrich) at a final concentration of 2.5µg/ 
mL and incubated for an hour at 37°C.  In the control samples, verapamil (Sigma-
Aldrich) was added to a final concentration of 50µg/ mL. After incubation, samples 
were washed and re-suspended in Hanks Balanced Salt Solution (HBSS)(Gibco) 
supplemented with 5% FBS (Gibco). Cell populations were stained with 1µg/ mL 
propidium iodide (Sigma-Aldrich) for exclusion of dead cells in analysis. Flow 
cytometry was performed using FACStarPLUS (Becton Dickinson, New Jersey, USA) 
and FACSAria (Becton Dickinson) and the analysis done using Summit 4.2 and 
FACSDiva respectively. 




Cells from HBM and cord blood were incubated with phycoerythin conjugated 
CD133/2 antibody (Miltenyi) diluted 1:10 in staining buffer (0.5% BSA/ 2mM EDTA 
in PBS). The cells are washed twice with staining buffer after incubation for 20mins at 
37°C and then suspended at 106cells/ mL of staining buffer for sorting. Isotype controls 
were in place and all samples were analyzed and sorted by flow cytometry using 
FACSAria and the software, FACS diva (Becton Dickinson). 
 
2.6 Proliferation Studies Using AlamarBlue® 
AlamarBlue® is a commercially available reagent used as an indicator of cellular health 
of the cells-of-interest. Viable cells in culture are able to convert resazurin, the active 
ingredient in alamarBlue® to resorufin. This is reflected as colour change from the 
nonfluorescence blue resazurin to the bright red fluorescent resorufin. 
 
AlamarBlue® is used as per manufacturer’s instructions, and incubated with the cells for 
four hours before absorbance is read at 590nm filter with Spectrophotometer 
(Beckmann, California, United States) 
 
2.7 Statistical Analysis 
Data were first checked for compliance to normal distribution. Parametric data were 
shown as mean ± standard error mean (SEM) and analysed using Student’s t-tests and 
one-way ANOVA where applicable. Non-parametric data were shown as median ± 
SEM and analysed using Kruskal-Wallis where applicable. A p-value of <0.05 was 
considered significant.  

























3 Cellular Component of Expressed Human Breast 
Milk 





Research in HBM has largely been focused on its nutritional value to the breastfed 
infant. As such, one can find numerous research articles on the nutrients like 
carbohydrates, proteins, lipids and vitamins (Mata and Wyatt 1971; Bracco et al. 1972; 
Ebner and Schanbacher 1974; Picciano and Guthrie 1976; Siimes et al. 1979; Packard 
1982; Bitman et al. 1983; Davies 1983; Howell et al. 1986; Morriss 1986; Goldman and 
Goldblum 1989; Jensen 1989; Canfield et al. 1991; Hamosh 1995; Koldovsky 1995; 
Lammi-Keefe 1995; Coppa et al. 1999).  On the other hand, research in the cellular 
component of HBM is a field less explored (Crago et al. 1979; Ho et al. 1979; Brooker 
1980; Davies 1983; Wirt et al. 1992; Xanthou 1997; Thompson et al. 1998).  
 
Working with colostrum donated from fifty-four healthy donors, Crago and team found 
a range of 1.1x105 to 1.2x107 cells per mL of colostrum (Crago et al. 1979). This 
cellular component comprises 30-47% macrophages, 40-60% polymorphonuclear 
leucocytes, 5.2-8.9% lymphocytes, and 1.3-2.8% colostral corpuscles. The team found a 
great variability in the total number of cells and distribution of various cell types both 
among individuals and also in the same individual studied longitudinally, although no 
significant increase or decrease in total number of cells per mL of colostrum were found 
(Crago et al. 1979). 
 
In the following year, Brooker studied the composition of HBM up to 110 days 
postpartum. He examined HBM derived from 30 lactating women and found that the 
population of intact cells was relatively low, greatly outnumbered by the membrane-
bound cytoplasmic fragments. In addition the immune cells, lymphocytes, macrophages 
and polymorphonuclear leukocytes have garnered more interest due to their role in 




conferring immune protection to the neonate against pathogens (Brooker 1980). The 
different cell types have been found to transfer cell-mediated immunity (Mohr 1973; 
Parmely et al. 1977), produce IgA antibodies (Murillo and Goldman 1970) and 
interferon (Emodi and Just 1974), and engulf enteric pathogens (Pitt et al. 1977). The 
epithelial cells on the other hand are subjected to much lesser scrutiny. He found the 
presence of three distinct epithelial cell types: secretory cells denoted by the presence of 
abundant cisternae of rough endoplasmic reticulum, lipid droplets and a Golgi apparatus, 
squamous epithelial cells which are derived from the stratified squamous epithelium of 
the galactophores and/ or the skin of the nipple and lastly, ductal cells which are found 
in clusters of two to four cells and they occur in small numbers (Brooker 1980). He also 
established that the secretory cells are commonly found up to 110 days postpartum 
whereas the duct cells are found only up to eight days postpartum.  
 
In this chapter, I aim to extend this body of work by examining the cellular component 
of HBM beyond one year postpartum in detail, which is more than 3 times the duration 
which Brooker et al has explored. HBM is dynamic in nature and examination of the 
cellular component of HBM beyond 110 days will allow us to explore the cellular 
changes beyond the first 3 months of lactation. I will also investigate the cell types by 
applying more modern stem cell techniques, based upon the surface markers that they 
possess. 
 
3.2 Cellular Content 
In order to reduce the possiblity of cellular death post expression of HBM, all the 
samples were processed within four hours post-collection. The cell concentration in 
milk ranges widely from 103 cells/ mL milk to 8x105 cells/ mL milk, with a mean RNA 




level of 2.6 ± 0.8 (SEM) pg per cell. No correlation was found between the duration of 
breastfeeding and cell concentration in HBM, in either inter-individual (n=40, r2 = 0.4) 
(Figure 3-1) or intra-individual samples (Figure 3-2, n=6, r2 < 0.03). Cellular content of 
expressed HBM comprised immune cells like neutrophils, basophils, monocytes, 
lymphocytes and macrophages as well as epithelial cells as published previously 
(Figure 3-3 & 3-4). A cell type which has not been characterised before was observed. 
These putatively novel cells were significantly smaller than the immune and epithelial 




Figure 3-1 Correlation of cell concentration in milk to the duration of 
breastfeeding. Cell concentrations were not related to the duration of breastfeeding in 
my study (R2 = 0.4) 
 






Figure 3-2 Correlation of cell concentration in milk to the duration of 
breastfeeding in 6 lactating females. Cell concentrations were not related to the 
duration of breastfeeding in all 6 females when their milk samples are analysed 
longitudinally (R2 < 0.03). 





Figure 3-3 Phase contrast image of total cell population in HBM. Neutrophils were 
recognised by their multi-lobed nucleus. Lymphocytes and monocytes were both 
circular and were differentiated by the nuclear cytoplasmic ratio. Lymphocytes have a 
large nucleus with a thin periphery of cytoplasm. The irregularly shaped lactocytes and 
macrophages were distinguished by the lipid inclusions exclusively found in the 
lactocytes. A group of cells with a high nuclear cytoplasmic ratio was observed. This 





                                                                                                                                    
Figure 3-4 Haematoxylin and eosin staining of cells directly spun down from HBM. 
The epithelial cells shown in high magnification here are larger than lymphocytes 








In order to further characterise the heterogeneous cellular population of HBM, I 
interrogated the cells for lineage specific markers in this mixed cell population. The 
presence of haemopoietic, mesenchymal and neural-epithelial lineage specific markers 
were investigated at both mRNA and protein level. 
 
3.3 Test for Various Lineage Markers 
3.3.1 Cell Markers of Haemopoietic Lineage 
 
 
Figure 3-5 RT-PCR of haemopoietic stem markers. mRNA of haemopoietic stem 
cells (HSC) markers: CD133 and CD34 were present in whole cell population (WCP) of 
HBM (Lane 1-3). These HSC markers are absent in MCF-7, a breast cancer cell line 
(Lane 4). Lane 5 displayed mRNA of the HSC’s markers on cells isolated from 
umbilical cord blood, a positive control. 
 
Firstly, I looked for the expression of CD34 and CD133 at the mRNA level. CD34 is a 
known haemopoietic stem/ progenitor and endothelial cell marker (Fina et al. 1990). 
CD133 has been associated with a variety of primitive cells in both haemopoietic and 
neural lineage (Yin et al. 1997). As shown in Figure 3-5, CD34 and CD133 are present 
in all three milk samples while absent in a breast adenocarcinoma cell line, MCF-7. 




This suggests the presence of haemopoietic stem/ progenitor cells in the cellular 
component of HBM.  
 
Next, I performed immunocytochemistry for CD34 on cytospun cells directly isolated 
from HBM and found high level staining even in my negative controls (Figure 3-6). 
This occurred despite employing several techniques to reduce this high level of 
background staining such as varying the blocking agent from 5% goat serum with 2% 
BSA to 10% goat serum with 5% BSA, to as high as 50% goat serum and varying the 
incubation time with the blocking agent from 30mins at room temperature to an hour at 
37°C to two hours at room temperature. This high background staining was not 
observed in other cell types tested, namely the human umbilical vein endothelial cells 
and erythrocytes (Fig. 3-6c, d). This problem is most likely due to the large amount of 
cellular debris and lipids present in expressed HBM. Hence, I attempted to optimise the 
sorting of cells from HBM for immunocytochemistry, as shown in Table 3-1. Despite 
the several rounds of optimisation, hematoxylin and eosin stained cells derived from 
cell pellets demonstrated persistence of high background staining (Figure 3-7). 
Method Procedure Undertaken 
A Centrifugation at 1,900rpm for 10mins thrice followed by incubation 
with trypsin/EDTA for 15mins followed by incubation in RPMI for 
1.5hrs before cytospun onto slides. 
 
B Centrifugation at 1,900rpm for 10mins thrice followed by three 
washes in RPMI before cytospun onto slides. 
 
C Centrifugation at 1,900rpm for 10mins thrice followed by incubation 
with trypsin/EDTA for 30mins followed by incubation in RPMI for 
2hrs before cytospun onto slides. 
 
D Centrifugation at 1,900rpm for 10mins thrice followed by incubation 
with culture medium for 2hrs before cytospun onto slides. 
                                                                                                                                     
Table 3-1: Optimisation strategy for isolation of cells for immunocytochemistry. 
 





Figure 3-6 CD34 staining. Whole cell population directly isolated from HBM (a-b, b 
without primary antibody), human umbilical vein endothelial cells (c, positive control) 





Figure 3-7 Hematoxylin and eosin staining. Whole cell population of HBM stained, 
with a high amount of debris despite multiple washes. Magnification of 4X. 




 Following this, I decided to use flow cytometry to investigate the protein level instead. 
Flow cytometry allows the analysis of a very large number of events, reducing errors of 
looking at too small a population as in the case of immunocytochemistry. In addition, 
flow cytometry does not require forceful spinning of cells down (with the debris) while 
allowing analysis of the cells in suspension. This reduces the clumps present, allowing a 
more reliable collection of results. The flow cytometer also allows the gating for the 
exclusion of cellular debris, typically in the bottom left hand corner of a forward-scatter, 
side-scatter plot. Appropriate isotypes were used to allow robust removal of 
autofluorescence. 
 
Next, I utilised flow cytometry in an attempt to delineate the cell types found within 
HBM. Flow cytometry of CD133, CD34 and CD117 were first carried out on a positive 
control using mononuclear cells (MNC) from umbilical cord blood collected from term 
pregnancies. In MNC of cord blood, I found 1.12% of the cells to be CD34+, a lower 
percentage of 0.41% of the cells being CD133+ and lastly, 1.28% of the cells to be c-
kit-positive. This is comparable to the published data on the cells present in cord blood 
(Nimgaonkar et al. 1995). The typical protein profile of the three haemopoietic stem/ 
progenitor cell markers was as shown (Figure 3-8). By subjecting the WCP of HBM to 
fluorescence activated cell sorting (FACS), I found a mean of 2.6±0.8% CD133-
positive cells, with 1.1±0.15% of the WCP being CD34 positive and 0% of the WCP 
being c-kit positive (Table 3-2, page 79). 
 























Figure 3-8 Staining for haemopoietic stem/ progenitor markers. WCP directly 
isolated from HBM are subjected to flow cytometry, analysing 20,000 events for each 
antigen (red), with an appropriate isotype control (green). 
 





Antigen  Other name            Expression determined by Flow Cytometry 
     Mean % No. of Samples SEM 
 
CD133  Prominin-like 1 2.6   4  0.8 
CD117  c-kit   0.0   3  0.0 
CD 24  BA-1   70.7   3  10.3 
CD29  β-1 Integrin  11.5   3  5.8 
CD49f  α-6 Integrin  11.4   3  7.3 
CDw338 ABCG2  21.1   3  1.8 
CD34     0.7   3  0.2 
Stro-1     27.8   3  9.1 
Nestin     4.7   3  0.2 
CK 5     0.9   3  0.2 
CK 14     0.2   3  0.2 
CK 18     2.0   3  0.1 
 
                                                                                                                                     
Table 3-2: Expression of selected proteins in WCP of HBM. 
 
 
3.3.2  Cell Markers of Mesenchymal Lineage 
Mesenchymal stem cells are able to differentiate into adipocytes, chrondrocytes and 
osteocytes (Pittenger et al. 1999). The established mesenchymal stem cells markers are 
Stro-1, CD105 as well as vimentin. However, CD105 and vimentin are also present on 
cells of the lympho-haemopoietic system. Specifically, CD105 is present on activated 
monocytes and macrophages and vimentin on lymphocytes and macrophages (Giorno 
1985; Rohde et al. 2006). Therefore, showing their presence on the WCP of HBM 
would not be indicative of mesenchymal stem/ progenitors in HBM. The immunogen 
for Stro-1 is still as yet unknown. I therefore decide to run RT-PCR for a terminal cell 
type of mesenchymal lineage. Three bone markers: osteonectin (ON), alkaline 
phosphatase (ALP) and osteopontin (OP) were investigated (Figure 3-9). ON, ALP, and 
OP are markers for early, intermediate and terminal bone respectively (Qi et al. 2003).  
 





Figure 3-9 RT-PCR for bone markers. ON, ALP and OP were present in WCP of 
HBM (Lane 1-3). These bone markers were absent in MCF-7 (Lane 4), an external 
negative control. mRNA from fetal mesenchymal stem cells, an early cell type of the 
mesenchymal lineage was used as an external positive control (Lane 5).  
 
 
Fetal mesenchymal stem cell (fMSC) is an early cell type of the mesenchymal lineage 
and is used as a positive control.  An increasing expression of the bone markers, with 
the lowest expression of the early marker and the highest expression of the late bone 
marker were noticed in all three samples, shown in Lane 1 to 3.  
 
I performed flow cytometry for Stro -1, an established mesenchymal stem cell marker. I 
found a mean of 27.8±9.1% of cells which are Stro-1-positive (Table 3-2, page 79).  
 
The RNA present in WCP of HBM containing early bone markers and presence of Stro-
1 as determined by flow cytometry, suggest the presence of mesenchymal stem/ 
progenitor cells in the heterogeneous population. The presence of late bone marker 
suggests the possibility of terminal mesenchymal cell type like bone being present in 
the WCP in HBM. 
 









Figure 3-10 Staining for mesenchymal stem/ progenitor markers. Whole cell 
population directly isolated from HBM and subjected to flow cytometry, analysing 
20,000 events for Stro-1 (red), with an appropriate isotype control (green). 
 
3.3.3 Cell Markers of Neural Lineage 
 
From Figure 3-11, it was observed that only nestin is expressed at comparatively high 
levels. Musashi-1 is a central nervous system (CNS) progenitor cell marker, which is 
important for determination of mammalian cell fate, maintenance of stem cell state, 
differentiation and tumorigenesis (Okano et al. 2005). Musashi-1 was found to be 
expressed in all three samples, although at very low levels in two of the samples (Lane 
1 and 2) (Figure 3-11). A similar pattern of gene expression was observed for a 
differentiated neural cell marker, neurofilament M (NFM), which is typically expressed 
in neurons (Figure 3-11).   
 
Nestin was expressed in a mean of 4.7±0.2% of cells in HBM by FACS analysis (Table 
3-2, page 79). 





Figure 3-11 RT-PCR for neural markers. Messenger RNA of musashi-1 (Msi), nestin 
(NES) and neurofilament-M (NFM) were observed in WCP of HBM (Lane 1-3). These 
neural markers were absent in MCF-7 (Lane 4), an external negative control. RNA 
directly isolated from human fetal brain was used as a positive control for the neural 











Figure 3-12 Staining for neural stem/ progenitor markers. Whole cell population 
directly isolated from HBM and subjected to flow cytometry, analyzing 20,000 events 
for nestin (red), with an appropriate isotype control (green). 
 




3.3.4 Cell Markers of Epithelial Lineage 
 
CK5, CK14 and CK18 are established markers used in characterisation of maturity of 
mammary epithelial cells. CK5 is a marker for mammary progenitor cells, CK14 is a 
marker for both mammary progenitor cells and mature myoepithelial cells, and CK18 is 
an established marker for mature luminal epithelial cells (Bocker et al. 2002). 




Figure 3-13 RT-PCR for epithelial cell markers. Messenger RNA of CK5, 14 and 18 
were present in WCP of HBM (Lane 1-3). The mammary progenitor cell marker, CK5 
and myoepithelial cell marker, CK14 were absent in negative control of mononuclear 
cells in peripheral blood (Lane 4) and present in MCF-7, a positive control (Lane 5). 
 
 
Flow cytometry showed a mean of 0.93±0.17% CK5+, 0.25±0.16% CK14+ and 
1.97±0.05% CK18+ cells in the cellular content of HBM with a typical flow cytometry 








































Figure 3-14 Staining for epithelial cell markers. Whole cell population directly 
isolated from HBM and subjected to flow cytometry, analyzing 20,000 events for CK5, 
CK14 and CK18 (red), with an isotype control (green). 
 
3.3.5 Cell Markers Representing other Functional Antigens 
 
CD24, β-1 and α-6 integrins are transmembrane glycoproteins involved in cell 
adhesions which have all been identified in MaSC (Shackleton et al. 2006; Smith 2006). 
Murine mammary cells within the lin-CD29hiCD24low population were found able to 
reconstitute an entire functional mammary gland demonstrating at the highest level, 
what would constitute a true stem cell (Shackleton et al. 2006). The presence of ATP 

















involved in the trafficking of biological molecules across membranes, is also 
characteristic of many stem/ progenitor cells and also cancerous cell lines (Challen and 
Little 2006). Therefore, in addition to lineage specific markers, I also attempted to 
investigate protein expression of these markers which have been implicated in the 
identification of MaSC, namely CD24, β-1, α-6 integrins and ABCG2. Through flow 
cytometry, I found positive expression of the four proteins (Figure 3-15) in percentages 
as shown in Table 3-2 (page 79). 






















Figure 3-15 Staining for other functional proteins. Whole cell population directly 
isolated from HBM and subjected to flow cytometry, analyzing 20,000 events for 
ABCG2, CD24, CD29 and CD49f (red), with an appropriate isotype control (green). 
 





3.4.1 Summary of Results 
Through the use of flow cytometry and RT-PCR, I have ascertained the positive 
expression of a large number of cell surface markers and intermediate filaments (IFs) 
within the cellular component of HBM. This includes stem/ progenitor markers of 
various lineages like CD133, ABCG2, nestin, Stro-1, CD24, β-1 and α-6 integrins and 
some of these markers have never been reported present in HBM or the cellular 
component of HBM. 
 
3.4.2 Critical Assessment  
My hypothesis was that adult stem/ progenitor cells are present in HBM. In order to 
determine the plausibility of this study, I investigated the cell surface markers and IFs 
on the cells of HBM using flow cytometry and RT-PCR to discover novel antigens that 
have never been investigated before. 
 
 
Positive staining of stem/ progenitor markers of various lineages suggested the presence 
of uncharacterised cell types in the cellular component of HBM. The staining of 
ABCG2 further ascertains that potential stem/ progenitor cells are present. CD24 is a 
glycoprotein that is expressed on the surface of most B lymphocytes while β-1 and α-6 
integrins interact with each other to form heterodimers. Interestingly, CD24, β-1 and α-
6 integrins have also been implicated in MaSC (Shackleton et al. 2006; Stingl et al. 
2006b). Shackleton et al have reported the isolation of mammary stem cell within the 
Lin-CD29hiCD24low population, with these cells able to reconstitute an entire 




functional mammary gland demonstrating at the highest level, what would be a true 
stem cell, at least in the murine model (Shackleton et al. 2006). Stingl et al on the other 
hand also showed subsets of cells from reduction mammoplasties that expressed highest 
levels of CD29 or CD49f and CD24 (termed the ‘‘double positive’’ population). These 
double positive cells were found to be enriched for mammary stem/ progenitor cells by 
transplanting these cells at limiting dilution into cleared fat pads (Stingl et al. 2006b). I 
have shown the presence of all these antigens on the WCP of HBM (n=3) at substantial 
amounts. 
 
I have also investigated the expression of a large number of IFs by flow cytometry, in 
view of their importance and specificity of their presence in cells. Intermediate 
filaments are one of the three major cytoskeletal protein filament systems of most 
vertebrate cells. They form networks that extend from the nucleus to the plasma 
membrane, attach to desmosomes, and interact with a variety of cell structures. They 
are essential in conferring tensile strength to the cells and play an indispensable role in 
determining the shape of cells (Markl and Schechter 1998). The different cytoplasmic 
IFs proteins are specifically expressed by different cell lineages: keratins in epithelia, 
vimentin in mesenchymal derived cells and tissues, desmin in muscle cells, glial 
fibrillary acidic proteins (GFAP) in astrocytes, and neurofilament proteins in neurons 
(Markl and Schechter 1998). Presence of keratins on mammary epithelium and the 
absence of desmin and vimentin in both epithelial and myoepithelial cells illustrate the 
specificity of expression of IFs (Franke et al. 1980). The presence of differentiated 
epithelial cells in HBM has been reported (Brooker 1980) and this correlates to my 
finding of CK14- and CK18-positive cells. The positive expression of CK5 and the 




neural IFs once again, suggests the presence of a yet still uncharacterised cell 
population in HBM. 
 
Epithelial and neural cells both descend from a common germ layer known as the 
ectoderm. The presence of nestin, which is a multipotent progenitor cell marker (Wiese 
et al. 2004), suggests the potential existence of a more primitive stem/ progenitor cell 
than mammary stem/ progenitor cells. 
 
In conclusion, my results suggest the presence of novel cell type(s) in HBM. From the 
various antigens found present as well as the known established cell types in HBM, 
there is a high likelihood that this novel cell type(s) is primitive in nature, and likely to 






























4 In Vitro Expansion of Adherent Cells in Selective 
Medium 




In the previous chapter, I have demonstrated the presence of novel markers on the 
cellular content of HBM. In this part of my thesis, an attempt to identify the possible 
cell types will be made. By drawing from the anatomical location and the current 
knowledge of cell types established in HBM, I speculate that these cells are most likely 
epithelial cells. This, in combination with the established positive expression of 
mammary stem cell markers; CD24, CD29, CD49f and ABCG2 suggests that these 
cells are likely to be primitive epithelial cells. 
 
The history of culture of epithelial cells in HBM dates back to 1972, where Beuhring 
and team introduced the derivation of epithelial cells from HBM to circumvent the 
difficulty in obtaining pure cultures of mammary epithelial cells. This method of 
obtaining epithelial cells from HBM and culturing them using Eagles’s basal medium 
with 30% fetal calf serum, polymixin, antibiotic and antimycotic solved the problem of 
contaminating fibroblasts which inevitably accompanied the mammary epithelial cells 
during biopsies and tumour explants,  which overgrows the epithelial cell types 
(Buehring 1972). Since then, there have been major improvements of the culture 
medium, which at its most initial form, is capable of achieving a confluent monolayer 
on a T75 flask over five days (Buehring 1972). Currently, the use of serum free defined 
culture medium has been formulated to grow MaSC as mammospheres, forming the 
gold standard for culture of MaSC (Dontu et al. 2003a). 
 
In Chapter 3, I have documented the difficulty in staining cells from HBM due to the 
high level of cellular debris present, leading to non-specific binding of antibodies. This 
hindered their further characterisation. In this part of my thesis, I explored the possiblity 
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of expanding these putative primitive epithelial cell types. Enrichment of these cells-of-
interests will enable more detailed characterisation of them and give some clue 
regarding their origin and behaviour. Taking into account the inclination of epithelial 
cells to be adhesion-dependent, I first explored cell expansion through two-dimensional 
monolayer cultures. I followed this up with a three-dimensional matrigel culture to 
simulate the in-vivo conditions within the mammary gland.   
 
4.2 Two-dimensional Monolayer Culture 
Cells isolated from gravitational centrifugation were plated into 24-well plates at a 
density of 105 cells/ ml of medium. This was left overnight in the incubator for the 
epithelial cells to adhere using a medium that selectively aided the growth of epithelial 
cells. The wells took 7 to 30 days to reach confluency with medium changes every two 
to three days. The non-adherent cells were removed by the series of medium changes.  
Confluent monolayers as shown in (d) of Figure 4-1 were then fixed for 
immunocytochemistry work.  
 
4.2.1 Growth Kinetics 
 
There was great variation in the growth potential of the isolated cells. Cells of sample 
shown in Figure 4-1 adhered within four days and reached confluency in approximately 
18.0±4.0 days (Figure 4-2).  
 
 




Figure 4-1 Two-dimensional monolayer of cultured epithelial cells. Cells were left 
to adhere for a day (a), after which attachment began (b) and dividing proceeds beyond 
day 4 (c) to day 18 (d) where a confluent monolayer was observed which is then fixed 




Figure 4-2 Metabolic activity of cells grown in 2-D cultures using AlamarBlue®. 
Standard error means are denoted by the black bars. 
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This growth trend was confirmed by the use of a metabolic assay (AlamarBlue®), where 
metabolic activity rises gradually until day 17 where it plateaus, coinciding with 
confluence of the culture (n=3) (Figure 4-2). 
 
4.2.2  Characterisation of Intermediate Filaments in Adherent Cells 
4.2.2.1  Detection of RNA by RT-PCR 
I performed RT-PCR for the immature CK5, and more mature lineage specific CK14 
and CK18. Identification of these IFs would demonstrate mammary epithelial cells of 
different maturity (Franke et al. 1979; Taylor-Papadimitriou and Lane 1987).  I also 
attempted to explore expression of nestin in the cultured cells as a follow-up to the 
presence of nestin-positive cells in uncultured WCP of HBM. Semi-quantitative 
analysis of the RT-PCR was done to investigate how the expressions of the IFs change 
when the cells are placed into culture. Comparatively, I found a similar expression of 
CK18 between culture-expanded cells and uncultured WCP, but a much lower 
expression of CK5 and CK14 in the uncultured WCP. This is demonstrated in Figure 4-
3 where CK5 and CK14 expression was below the detection threshold of RT-PCR, 
while CK18 was readily detected in cells directly isolated from milk. This suggests that 
epithelial cells are sustained in the adherent monolayer. There seemed to be an increase 
in the mammary progenitor population as indicated by the increase in mRNA level of 
CK5. Consistent with my earlier findings [Section 3.3.3], I also found the presence of 
nestin in the cultured cells (Figure 4-3).   
 




Figure 4-3 RT-PCR of intermediate filaments. Expression of CK5 and CK14 were 
up-regulated in cultured cells. Similar expression of CK18, nestin and GAPDH in the 
cells isolated from HBM and culture were observed. 
 
4.2.2.2  Detection of Protein by Immunocytochemistry 
4.2.2.2.1  Single staining with horseradish peroxidase 
Positive staining for CK5, 14, 18, 19 and nestin were ascertained by comparing with the 
negative controls and the percentages of stained cells were counted. I noted 50.5±7.0% 
positive staining for CK5 (n=21), 22.3±3.9% positive staining for CK14 (n=24), 
42.0±7.4% staining for CK18 (n=16) and 32.4±6.8% staining for CK19 (n=17). In 
terms of nestin staining, I observed 14.2±3.0% of nestin-positive cells in the cultures 
(n=17). In line with other reports, we found positive staining for epithelial specific 
CK18 and CK14 cells. From the counting of stained cells and as shown in Fig 4-4 and 
4-5, we observed not only a higher percentage of cells stained with CK18 and also at a 
much greater intensity compared to CK14. Interestingly, I observed a population of 
cells which co-expressed both nestin and CK5 in cells cultured from HBM (Figure 4-6). 
 




Figure 4-4 Immunocytochemistry for CK18. Homogenous positive stainings of 
cultured MCF-7 cells were observed (a-c) (positive control, c without primary antibody). 
In the cultured cells, heterogeneous staining indicates differential expression of CK18 
(d, e). Erythrocytes serve as negative control (f). Magnification of 4X (a, b), 20X (c,e,f) 





Figure 4-5 Immunocytochemistry for CK14. Lighter stainings were observed for 
CK14, which stained 22.3±3.9% of the cultured cells (a-e). Positive staining for CK14 
was done by comparing with the internal negative control without 1º antibody (f).  
Magnification of 20X (a, d, e, f) and 40X (b, c). 
 





Figure 4-6 Immunocytochemistry for CK5 and nestin. Nestin staining (red arrows) 
were observed in 14.2±3.0% (n=17) of the cells (a, b). 50.5±7.0% (n=21) of the 
cultured cells stained for CK5 (blue arrow) (c). Positive stainings were determined by 
comparing with internal negative controls without primary antibody (d). Magnification 
of 40X (a) and 20X (b, c, d). 
 
 
CK5 and CK14 were not expressed in HBM by means of RT-PCR but shown to be 
present in culture-expanded cells from HBM. Hence, I segregated the staining profile of 
the above IFs based on the number of the days the cells were cultured with the intention 
of looking for trends of change in expression of the 5 IFs. I segregrated the staining 
profile into three different culture periods, between 7 and 10 days (denoted as EM), 11 
and 20 days (denoted as MM) and beyond 21 days (denoted as LM). These findings 
were tabulated as shown in Table 4-1. There was statistical difference found only in 
CK18 (p-value = 0.04, ANOVA, Kruskal-Wallis test).  




 EM MM LM 
CK5 53.0±11.3 59.1±15.9 44.1±11.6 
CK14 21.2±3.7 18.4±7.9 26.0±6.1 
CK18 22.6±2.7 74.0±11.1* 22.4±9.2 
CK19 24.4±5.8 28.4±8.4 32.0±17.7 
Nestin 15.8±5.6 14.2±4.5 6.73±2.1 
                                                                                                                                     
Table 4-1: Expression of IFs based on duration of monolayer cultures. 
 
4.2.2.2.2  Dual staining with fluorescent tags 
In order to delineate the identity of these culture-expanded cells, IF proteins were 
stained using double labelling of nestin with CK5, 14, 18 and 19. There is as yet no 
definitive marker to demonstrate identity of MaSC. However, there have been reports 
on the use of dual staining to suggest identity as a mammary stem/ progenitor cell. 
Previous publications have shown that the myoepithelial and luminal epithelial cells 
were derived from the same progenitors. These progenitors co-express CK14 and CK18 
and lose one of the two markers when differentiate into one specific terminal epithelial 
cells (Pechoux et al. 1999). CK5, 14 and 19 have also been proposed as mammary stem/ 
progenitor markers, though not definitively as CK14 is also a marker of myoepithelial 
cell and CK19 being a marker of luminal epithelial cells, like CK18 (Bocker et al. 2002; 
Boecker and Buerger 2003). In congruence with the earlier findings on 
immunocytochemical staining of single antigens through horseradish peroxidase, I 
observed positive staining for all 5 IFs (Figure 4-7, 4-8). Using fluorophore reporter 
tags, I observed 47.2±7.6% of cells being CK5-positive, 17.8±3.7%, 28.3±6.5 and 
23.6±5.1% being CK14-, 18- and 19-positive respectively. Expression of nestin was 
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present in 16.0±2.6% of cells counted. Although some differences in levels of positivity 
were observed particularly for CK18 and CK19 between detecting with horseradish 
peroxidase and fluorophore reporter, these differences turned out insignificant (p-
value > 0.2), suggesting no differences between the staining methods. Nestin, a 
multipotent stem/ progenitor cell marker was found present in the cultured cells at both 
mRNA and protein level (Figure 4-3, 4-6 and 4-8). Nestin was co-expressed with CK19 
(24.4±3.6%), CK5 (11.4±4.2%), CK14 (3.7±1.5%) and CK18 (3.3±2.7%) in decreasing 
frequencies (Figure 4-8).  




Figure 4-7 Expression of cytokeratin markers in cells cultured from HBM.  
Fluorescent immunocytochemistry imaging of dual staining for CK14 (red), and CK18 
(a-b), CK5 (c-d) or CK19 (e-f) (green). CK18+ luminal epithelial cells were round and 
larger when compared to the CK14+ myoepithelial cells, which appears spindle-shaped 
(a). Scale: 50µm. 




Figure 4-8 Expression of the multipotent marker, nestin with cytokeratins. Dual 
fluorescent staining for nestin (red) with CK 5 (a-c), CK14 (d-e), CK 18 (f-g) or CK 19 




4.3 Three- dimensional Culture on Matrigel 
Three-dimensional culture of the epithelial cells was carried out to simulate a 
physiological relevant microenvironment, to allow stromal-epithelial interactions, 
mimicking the in vivo development of mammary gland. Matrigel, generated from 
Engelbreth-Holm-Swarm sarcoma was chosen as it contains not only basement 
membrane components (collagens, laminin, and proteoglycans) but also matrix 
degrading enzymes, their inhibitors and growth factors. In addition, there have been 
several reports of positive cultures of luminal, myoepithelial and precursor cells in 
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matrigel forming acinus-like structures, solid colonies and terminal ductal lobular units 
respectively (Petersen et al. 1992; Gudjonsson et al. 2002b). 
  
4.3.1  Growth Kinetics 
Cells grown as monolayers were trypsinised and cultured in matrigel-coated plates with 
the same medium. Matrigel is believed to induce differentiation of the cells, as has been 
reported by Dontu’s group using mammary stem/ progenitor cells isolated from 
reduction mammoplasties (Dontu et al. 2003a). Cells plated on matrigel-coated plates 
were cultured for 16±2days (n=40) before being used for immunocytochemistry.   
 
4.3.2  Characterisation of Intermediate Filaments 
I performed immunocytochemistry on the cells grown in matrigel coated plates and 
observed 52.4±6.2% (n =10) of the cells being nestin-positive. This is a steep increase 
of nestin’s expression from the 34.2 ± 4.3% (n= 21) in cells grown as monolayers. A 
mean percentage of 50.5±13.3% (n=8) cells in matrigel cultures were CK5-positive. 
46.2±11.7% (n=9), 33.4±14.4% (n=5) and 34.6±9.6% (n=8) of the cells grown in 
matrigel were found CK14-, CK18- and CK19-positive respectively. 
 
There were no differences in the proportion of positively-stained cells for each IF 
between two and three dimensional cultures as shown in Table 4-2 except for nestin.   




 2D 3D p-value 
CK5 58.5±6.5 50.4±13.3 0.56 
CK14 34.6±5.3 46.2±11.7 0.31 
CK18 48.4±7.6 33.4±14.4 0.24 
CK19 43.8±6.4 34.6±9.6 0.44 
Nestin 34.2±4.2 52.4±6.2 0.02 
 




4.4.1 Summary of Results 
From the growth kinetics, it is evident that epithelial cells from HBM have a wide range 
of proliferation profile, and that they are able to proliferate in both two and three-
dimensional culture systems. 
 
I have noted the presence of nestin and CK18 mRNA on cells directly derived from 
HBM (Figure 4-3).  Interestingly, these two IFs as well as CK5 and CK14 were 
expressed when cells from HBM were cultured. From the cells directly isolated from 
HBM, using semi-quantitative RT-PCR, I observed a similar amount of staining for 
CK18 whereas after culturing these cells as monolayers, I observed the appearance of 
CK5 and CK14. 
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From the co-staining experiments, I observed that heterogeneous cultures of nestin, 
CK5, CK14, CK18 and CK19 were common and that nestin had the highest proportion 
of co-staining with CK19, followed by CK5 , CK14 and lastly, CK18 (Figure 4-8).   
 
4.4.2 Critical Assessment 
4.4.2.1  Growth Kinetics 
I was able to grow the cells isolated from HBM both in two and three-dimensional 
cultures although not in a manner I have anticipated. Various groups have grown cell 
lines on three-dimensional in vitro culture models and observed the formation of 
structures resembling those in the mammary glands (Bae et al. 1993; Krause et al. 2008). 
I sought to investigate the formation of acinar structures using cells from HBM with 3D 
matrigel cultures but did not observe any formation of complex structures similar to 
acini.  
 
4.4.2.2  Pattern of Staining 
4.4.2.2.1 Two-dimensional monolayer cultures 
CK5 and CK14 were not detected in the WCP of HBM but appeared de novo in the 
culture expanded cells (Figure 4-3 and 4-7). This could be explained in three ways. The 
first explanation is that CK5- and CK 14-positive cells originated from either the nestin-
positive or CK18-positive cells or even both of them. Nestin is a well-characterised 
marker of multipotent progenitor cells and is closely associated with stem cell 
populations in bone marrow (Kabos et al. 2002), neural (Lendahl et al. 1990; 
Dahlstrand et al. 1992), pancreatic (Zulewski et al. 2001) and epithelial (Toma et al. 
2001) tissues. This in combination with the presence of nestin+/ CK5-, nestin+/ CK5+, 
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and nestin-/ CK5+ cell types (Figure 4-8) suggest that nestin+ cells found in HBM 
might be the precursor cell type.  
 
Alternatively with the semi-quantitative RT-PCR results taken into consideration, the 
other possible explanation for my observations would be that the culture media 
selectively enabled the CK5- and CK14-positive cells to expand more than the CK18-
positive cells. This would explain why these cells although present in low proportions 
in WCP of HBM, which were insufficient to give a positive signal during RT-PCR, 
manage to give positive signals for CK5 and CK14  after being cultured. 
 
The third explanation for my observation would that the culture media had brought 
about dedifferentiation of the CK18-positive cells into the CK5- and CK14-positive 
cells. In addition to explaining the appearance of bands for CK5 and CK14 in Fig. 4-3, 
this explanation would also account for the larger band of nestin observed in Fig. 4-3. 
 
4.4.2.2.2 Three-dimensional matrigel cultures 
The higher expression of nestin exhibited by cells cultured in matrigel-coated plates 
suggests a possible dedifferentiation of the epithelial cells, which contrasted with Dontu 
et al’s findings that matrigel induces differentiation into terminal structures (Petersen et 
al. 1992; Gudjonsson et al. 2002b; Dontu et al. 2003a). The lack of statistical 
significance in the cytokeratin staining however suggests that my postulation of 
dedifferentiation, based on the expression of nestin is unsubstantiated. 
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4.4.2.3  Hierachy of Adherent Cells in HBM 
Based on the IFs found on the cells in HBM as well as established information of these 
IFs, I postulate a hierarchy of cells within the lobulo-alveoli structure (Figure 4-9). I 
have shown that expressed HBM is a novel source of nestin+ putative stem cells. The 
capability of these nestin-positive cells in HBM to differentiate into cell types of other 
lineages should be explored since reports of nestin-positive stem cells 
transdifferentiating into other cell types are numerous (Zulewski et al. 2001; Kabos et al. 
2002; Amoh et al. 2005). 
 
Due to their partial co-expression with CK5 and anatomical origins, I postulate that they 
are mammary stem/ progenitors, which have been shown present. However, we will not 
be able to isolate the primitive cells-of-interest with these IFs, as they are intracellular 
and cells will have to be permeabilised, thereby destroying their plasma membrane. In 
my following chapters, I hence decide to use two surface markers, known to exist on 
stem cells, to isolate these primitive cells-of-interest to carry out further characterisation 
in order to ascertain their stemness. 
 





Figure 4-9 Flow chart for hierarchy of stem/ progenitor cells of mammary lineage. 



























5 Isolation of Stem/ Progenitor Cells in Expressed 
Human Breast Milk by Hoechst Dye Exclusion 
 




In the previous two chapters, I have firstly established the presence of yet-unknown 
cells in HBM and secondly, identified the presence of nestin-positive cells in HBM. I 
postulate that these nestin-positive cells are the most primitive cell type present in HBM. 
As it would not be possible to prospectively isolate them using nestin which is an 
intermediate filament, I decide to look for appropriate cell surface proteins that are 
commonly found on stem/ progenitor cells to attempt the isolation of these cells. 
 
 The use of cell surface markers to isolate cells is ideal as we would then be able to 
isolate viable stem/ progenitor cells. In fact, there are several cell surface markers that 
are already commonly in use to isolate primitive cells. One of the newer markers found 
by Goodell and team in 1996 is cell membrane channel which seem to be present on 
haemopoietic stem cells (Goodell et al. 1996). 
 
ABCG2 proteins function as channels on cell membranes to allow active efflux of 
substances, including toxins. The functionality of these channels can be demonstrated in 
vitro by the cells’ ability to efflux Hoechst dye. The group of cells capable of active 
efflux of Hoechst dye are termed the side-population (SP). Goodell et al. found an 
enrichment of haemopoietic stem cells in the SP of bone marrow (Goodell et al. 1996). 
Since then, SP has been reported in many stem cell populations, including mammary 
stem/ progenitor cells (Dontu et al. 2003a; Challen and Little 2006). Islam et al also 
found the co-localisation of nestin and the ABCG2 protein, on the same cells of many 
neurospheres (Islam et al. 2005) while Hayashi and team have made use of FACS and 
cell surface markers integrin α6 and CD71 to enrich for postulated corneal stem/ 
progenitor cells which he showed to have higher clonogenic capacity, a larger 
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proportion of non-dividing cells, and also express a higher level of ABCG2, a marker 
for stem/ progenitor cells (Hayashi et al. 2008).  
 
Hence in this chapter, I sought to identify viable cells-of-interest by this property of 
Hoechst dye exclusion in HBM, with the aim of isolating and characterising the 
primitive cell types. 
 
 
5.2 Occurrence of Side-population 
 
In cells directly isolated from HBM, I observed a side population (SP) that excluded 
Hoechst 33342 dye (Figure 5-1a). This group of cells was absent in the controls where 
Verapamil was used to block the membrane transporters (Figure 5-1b). I repeated 
Hoechst dye exclusion experiments on 47 milk samples (from 7 different mothers at 
various intervals) and found a distinct SP in 40 of the 47 samples (85.1%). A mean of 
2.1±0.3% of the entire cellular component was found within the SP. There was no 
significant correlation between samples from different donors as well as between 
samples collected from the same donor over a period of six months (Figure 5-2). This 
indicated that SP exists in HBM at a relatively constant percentage throughout duration 
of lactation.  
 




Figure 5-1 Hoechst 33342 exclusion by SP in HBM. SP can be identified in 
approximately 2% of WCP (gated R2), while the majority of cells (ungated) stained 
intensely with Hoechst (a). Verapamil block the ABCG2 channels and serve as a 




Figure 5-2 Correlation analysis of SP with duration of breastfeeding. Scatterplot 
showed the lack of correlation between the percentage of SP cells and the duration of 
breastfeeding.  
 




Unless stimulated by granulocyte stimulating factor, adult peripheral blood does not 
usually contain stem/ progenitor cells and therefore it would be a good external negative 
control, while mononuclear cells from umbilical cord blood were used as positive 
controls to establish the method of Hoechst dye exclusion. Mononuclear cells from 
peripheral blood were incubated with Hoechst 33342 dye and no SP was observed 




Figure 5-3 Hoechst dye exclusion of controls. Incubation with Hoechst alone (a) was 
no different from the Verapamil control (b) in mononuclear cells of peripheral blood, 
indicating absence of SP whereas a clear region of SP cells was present in the 
mononuclear cells from umbilical cord blood (c) which is absent when cells were 
incubated in the presence of Verapamil (d). 
Chapter 5. Isolation of Stem/ Progenitor Cells in Expressed HBM by HDE  
 
 113 
5.3 Characterisation of Side-population 
Cells in the SP and non-SP were collected separately and expression of various proteins 
investigated by immunofluorescence and flow cytometry (n ≥ 3). The sorted cells were 
stained for nestin and CK18 using immunofluorescence. SP cells were predominantly 
nestin-positive (89.7±4.7%), compared to negligible expression in non-SP cells 
(0.67±0.54%, p-value < 0.001) (Figure 5-4b). In contrast, more non-SP than SP cells 
stained positive for the mature epithelial marker CK18 (39.4±9.8 vs 5.3±2.0%, p-value 
= 0.026) (Figure 5-4c compared to 5-4d). 
 
Figure 5-4 Immunocytochemical staining for nestin and CK18. Nestin staining of 
SP demonstrated predominantly positive cells (green cytoplasmic staining) (a) while 
largely negative in non-SP cells (b). On the other hand, CK18 staining was found 
predominantly in non-SP cells (c-d). Nucleus counterstained in DAPI. Magnification of 
20X. 
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The expression of ABCG2, CD45, CK5 and CK14 were investigated with flow 
cytometry (Figure 5-5). The low expression of ABCG2 in both populations suggested 
the presence of other protein channels responsible in bringing about the efflux of 
Hoechst dye. Presence of CD45 was observed in both SP and non-SP cellular fractions 
(5.7±2.2% vs 12.7±4.6%, Figure 5-5a). This illustrates the contribution of haemopoietic 
cells to both populations. A smaller proportion of SP cells was found CD45-positive as 
compared to non-SP cells, although not reaching statistical significance. Expression of 
the CK5 and CK14 were comparable between the SP and non-SP cells (9.4±4.4% vs 




Figure 5-5 Flow Cytometry for CD45, ABCG2, CK5, CK14 and CK18. Comparison 
of expression of CD45 and ABCG2 (a), of CK5, CK14 and CK18 (b) between the SP 
and non-SP.  
 
 
In order to further delineate the two populations, I stained flow-sorted SP and non-SP 
for the expression of other epithelial and non-epithelial markers (Table 5-1). EPCAM, 
which is known to be expressed by bi-potent mammary progenitor cells, which give rise 
to EPCAM-positive luminal progenitors and EPCAM-negative myoepithelial 
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progenitors (Stingl et al. 2001; Eirew et al. 2008), was found to be enriched in the SP 
fraction (50.6±8.6% vs 18.1±6.0%, p-value = 0.02). We found a small increase in 
CD31-positive cells in the SP (1.9±.2% vs. 0.7±0.3%, p-value = 0.04) over the non-SP 
fraction, which may indicate the presence of haemopoietic and/ or endothelial cells, 
which are known to express CD31 (Watt et al. 1995), within the SP. 
 
Taken together, the enrichment of cells with primitive markers EPCAM and nestin and 
the lower expression of the mature epithelial marker CK18 in the SP cellular fraction of 
WCP suggest the presence of MaSC within uncultured WCP in HBM. 
Chapter 5. Isolation of Stem/ Progenitor Cells in Expressed HBM by HDE  
 
 116 
Table 5-1: Antigens expressed on the SP and NSP in HBM. 
 
5.4 Mammosphere Culture of Selected Populations 
5.4.1 In Vitro Expansion of Side-population 
Expansion of these rare cells is important in an attempt to increase cell numbers to work 
with. There is also a need to prove clonogenicity and self-renewal ability of these cells 
to identify them as stem cells (Lajtha 1979; Humphries et al. 1981). Prior to this, I 
devised a series of positive controls as will be discussed in Section 5.4.1.1. 
 
Chapter 5. Isolation of Stem/ Progenitor Cells in Expressed HBM by HDE  
 
 117 
5.4.1.1 Positive Controls for Mammosphere Culture 
To prepare for mammosphere cultures for my cells-of-interest, there is a need to 
ascertain the functionality of my Hoechst dye exclusion protocol as well as 
mammosphere medium.  
 
5.4.1.1.1 Culture of neurospheres 
Using neurospheres as a working system for the culture of spheroids in vitro, I 
embarked on the generation of neurospheres derived from fetal brain tissues. Single 
cells derived from eight various regions of the brain were plated into neurosphere 
medium to grow. Neurospheres as shown in Figure 5-6 were then observed after two to 
four weeks of culture. 
 
 
Figure 5-6 Free-floating neurospheres cultured from fetal cells. Spheres derived 




Overall, spheres were observed growing in 5 out of 5 samples and across each sample, 
spheres generally grow from all regions. Morphologically, the spheres were identified 
by their phase-bright appearance and regular cell membranes and microscopically, there 
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is little difference in the physical appearance of the neurospheres derived from the 
different regions of the second trimester fetal brain (Figure 5-6). The number of spheres 
larger than 50µm in diameter were counted and a low efficiency of lesser than 0.09% 
across the second trimester samples. From the fetus of the smallest gestational age 
(14+6weeks), we observed the lowest neurosphere initiating assay in the hippocampus 
(0.002±0.00004%) and the highest in the brain stem (0.0074±0.009%) and from the 
fetus of the oldest gestational age (23+1weeks), we observed once again, the lowest 
neurosphere initiating assay in the hippocampus (0.006±0.00004%). However, the 
anterior cerebrum was found to have the highest efficiency in neurosphere generation 
this time round (0.066% ± 0.0162%) (Figure 5-7). From the graphical representation in 
Fig. 5-7, an increasing trend for neurospheres’ initiating ability was observed between 
14weeks and 23weeks, suggesting that the largest number of neural stem cells in second 
trimester fetus is present in the later phase of second trimester, specifically 20weeks in 
the case of subventricular zone (SVZ) and hippocampus and 23+1weeks for the other 
five regions of the fetal brain. 
 
 
Figure 5-7 Neurospheres-initiating efficiency of cells derived from various regions 
of the fetal brain. Neurospheres initiating efficiency rises with increasing gestations. 
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To examine cell-specific antigen expression on the neurospheres, we allowed the 
neurospheres to attach on poly-lysine coated cells for four hours at 37°C before fixing 
and staining them. We observed across the neurospheres, positive staining for nestin, B-
tubulin III, GFAP as well as PDGFRα, ascertaining the heterogeneity of cell 
composition in neurospheres (Figure 5-8). 
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I next differentiated the cells by plating them onto poly-L-ornithine coverslips in 
medium containing 1% FBS and no mitogens for one week. I observed the spreading of 
the cells onto the coverslips with short processes branching out and a week later, an 
entire network of cells intertwined. The cell types of these cells were confirmed by 
staining with β-Tubulin III, GFAP and PDGFRα (Figure 5-9).  






































Figure 5-9 Differentiated cells from neurospheres derived from various regions of 
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5.4.1.1.2 Culture of mammospheres from MCF-7 
In addition to the use of fetal neural tissues for the generation and characterisation of 
neural stem cells, I also attempted to isolate mammosphere cultures using a breast 
carcinoma cell line, MCF-7. SP and non-SP cells from MCF-7 cultures (Figure 5-10a) 
were singly-sorted into serum-free mammosphere culture medium, where free-floating 
mammospheres were observed (Figure 5-10b) from the SP fraction of the cell line, but 
not from the non-SP fraction.  These MCF-7 SP derived  mammospheres stained 
positive for CD49f, CD326, CK18, CK14, CK5 and CK19, and negative for CD45 and 
CD10, an immunophenotype consistent with MaSC cultured as mammospheres (Figure 
5-10c).  
 
This verified two important points, first being that cells sorted through flow cytometry 
were still viable and capable of proliferating and the second point that the 
mammosphere culture media I used was able to generate mammospheres from the 
relevant cells. 




Figure 5-10 Culture of SP of positive control, MCF-7.  Flow cytometry profile of 
MCF-7, a breast cancer cell line from which the SP was sorted out 9(a) grew into 
mammospheres after ten days (b). Immunocytochemical staining demonstrated that they 
were CD10 and CD45 negative, and positive for CK5, CK14, CK18 and CK19, and 
positive for alpha-6 integrin (CD49F) and CD326 (c, green stains with DAPI nuclear 
counterstaining).  
 
5.4.1.2 Single Cell Cultures 
Dontu and team found that SP cells obtained from mammary tissues are able to grow 
clonally (Dontu et al. 2003a). Singly-sorted SP cells were found to be able to form 
mammospheres which were not replicated in non-SP cells. As such, I attempted to 
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replicate this finding in SP cells of HBM at clonal densities. SP and non-SP cells were 
sorted singly into each well of a 96-well plate and incubated in mammosphere medium. 
I repeated this for four 96-well plates, using four different milk samples. However, all 
768 wells failed to generate any mammospheres over a period of four weeks in culture.  
 
5.4.1.3 Low Density Cell Cultures 
Next, I investigated whether the culture of higher densities of SP cells may allow the 
generation of mammospheres. This approach may allow paracrine factors to assist in the 
generation of mammospheres, as found in other culture systems for instance, MSC 
systems which rely on paracrine signalling for the rapid log phase growth (Gregory et al. 
2003). Culturing of HBM SP and non-SP cells at a low density of 3x103 cells/ cm2 on 
low-adherence 96-well plates however, did not generate any mammospheres over four 
weeks. Further to this, I investigated the effects of different growth factors and substrata, 
which may contribute towards the successful expansion of these sorted cells. 
 
5.4.1.4 Optimisation of Expansion of Sorted Cells 
5.4.1.4.1 Use of growth factors 
Growth factors are proteins that bind to receptors on the cell surface, with the primary 
result of activating cellular proliferation and/ or differentiation. Epidermal growth factor 
(EGF) and basic fibroblast growth factor were chosen as they are already being used in 
mammosphere medium. In additon, EGF receptors have been found on mammary cells 
(Smith et al. 1984; Smith et al. 1989).  
 
Chapter 5. Isolation of Stem/ Progenitor Cells in Expressed HBM by HDE  
 
 126 
Fetal bovine serum contains a variety of mitogenic growth factors known to aid growth 
of cells and is routinely used in culture medium.  
 
The niche effect or microenvironment also plays an important role in stem cell biology 
(Fuchs et al. 2004). To simulate the signalling of a typical niche of these SP cells, 
conditioned medium gathered from lactocyte culture were added into the mammosphere 
medium at various concentrations (Table 5-2). However, despite daily inspection of the 
wells over 2 weeks, no increase in cell numbers to suggest the expansion of the SP cells 
was observed. Cells did not adhere and blebbing of the cell membrane characteristic of 
apoptosis was observed (Kerr et al. 1972; Wyllie et al. 1980). 
 
I repeated the sets of single cell and low density culture experiments, with 
modifications to the mammosphere medium, altering serum and other growth factors as 
indicated in Table 5-2, with the aim of successful optimisation of culture medium for 
growth of SP cells in WCP in HBM. However, none of these approaches were 
successful in the isolation of mammospheres. Reductions of AlamarBlue® was 
quantitated for each variable in the culture media as shown in Table 5-2 and compared 
to the mitomycin-treated cells, where no difference was observed, suggesting the lack 
of cellular proliferation. 
 




Substances added into mammosphere medium 
Fetal Bovine Serum (%) 1 3 5 10 20 
Epidermal Growth Factor (ng/ ml) 20 40 60 80 100 
Basic Fibroblastic Growth Factor (ng/ ml) 20 40 60 80 100 
Conditioned Medium (%) 1 5 20 50 80 
 
Table 5-2: Substances for optimisation of culture medium. The four substances, 
believe to aid cell growth were added in increasing amount as indicated above to 
optimise the growth of SP cells from HBM. 
 
 
5.4.1.4.2 Use of substrata 
Within the mammary tissue, the various cells lie in an extremely complex ECM. This 
ECM contains collagens, fibronectin, laminin, glycosaminoglycans and others to 
interact with the cells, exchange signals and information, allowing the cells to respond 
accordingly, for instance repair of damaged cells or regeneration of epithelial cells 
when desired. I used various substrata (matrigel, gelatin, collagen and fibronectin) to 
line the bottom of the wells on which SP cells were grown. However, despite culturing 
them for up to 30 days, no proliferation under daily visual inspection was observed 
(Figure 5-11).  




Figure 5-11 Optimisation of culture medium using various substrata. Growth of 




5.4.1.5 Mid Density Cell Cultures 
Mid density cell cultures were established by seeding the cells at a higher density of 
9.3x103cells/ cm2 to allow the cells to interact with each other. This is to allow the cells 
to aid growth synergistically, through exchange of signals.  Under visual inspection 
every two to three days over a period of four weeks, no increase in cell numbers was 
observed. 
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5.5 Methylcellulose Culture of Selected Population 
5.5.1 Positive Controls for Methylcellulose Cultures 
As an appropriate control, I sorted umbilical cord blood for SP cells, and plated them as 
SP and non-SP cells (Figure 5-12a) in methylcellulose. After two weeks, I observed the 
development of multi-lineage colony forming units (CFU) from the SP and not the non-
SP fraction of umbilical cord blood (Figure 5-12b). This verified two important points; 
first being that cells sorted from the FACSAria are still viable and capable of 
proliferating and differentiating, a conclusion synonymous with Section 5.4.1.1.2 and 





Figure 5-12 Culture of SP from umbilical cord blood cells. Flow cytometry profile 
of umbilical cord blood with the SP sorted out for culture in methylcellulose (a), 
confirming the presence of burst forming unit-erythrocyte (BFU-E), colony forming 
unit-erythrocyte (CFU-E), colony forming unit-macrophage (CFU-M), colony forming 
unit-granulocyte,erythrocyte,  macrophage, megakaryocyte (CFU-GEMM)  as well as 
colony forming unit-granulocyte, macrophage (CFU-GM) in the SP of cord blood (b). 
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5.5.2 In Vitro Expansion  
 
As the SP fraction in bone marrow is enriched for HSCs (Goodell et al. 1996), and 
because of the abundance of haemopoietic cells found in HBM, I investigated HBM for 
the presence of haemopoietic stem cell types, by subjecting the sorted cels into the 
above methylcellulose culture system. SP and non-SP fractions of HBM were cultured 
in methylcellulose to induce the formation of haemopoietic colonies. However, I did not 
find any expansion into haemopoietic colonies (n=5) from either SP or non-SP cellular 
fraction of HBM.  
 
5.6 Discussion 
5.6.1 Summary of Results 
In this chapter, I investigated the presence of SP cells within HBM and used it as a 
putative marker of primitive cell types. SP cells from HBM are enriched for primitive 
nestin-positive cells and depleted of more mature epithelial cell types which were 
CK18-positive. The presence of SP coupled with nestin-positivity and CK18-negativity 
suggest their stem/ progenitor cells’ identity. Using flow cytometry, I attempt to look 
for differences between the SP and non-SP fraction for mammary stem cell, mammary 
epithelial and even non-epithelial markers. I found minimal differences between the two 
populations of cells except EPCAM and CD31 that are statistically significant (p-value 
of 0.02 and 0.04 respectively). I next investigated the cells’ potential to self-renew and 
differentiate down lineages. However, despite attempting to grow mammospheres at 
single cell, low-density and mid-density, no mammospheres were observed. Neither the 
addition of various growth factors at varying concentrations nor the use of various 
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substrata successfully yielded the culture of mammospheres. Controls for spheroid stem 
cell culture using fetal neural stem cells and breast carcinoma cell line, MCF-7 yielded 
positive results validating the techniques utilised in pursuing this objective. The attempt 
to delineate the identity of SP cells in HBM using haemopoietic assay confirmed their 
non-haemopoietic origin.  
 
5.6.2 Critical Assessment 
5.6.2.1 Isolation of Cells 
I have reported for the first time, the presence of SP cells in HBM. This Hoechst efflux 
phenomenon has proven to be a valuable strategy for isolating stem/ progenitor cells 
from various tissues which do not yet have any established cell surface markers. Cells 
with an SP phenotype have been described in many tissues including skeletal muscle, 
lung, liver, heart, testis, kidney, skin, brain and also the mammary gland (Challen and 
Little 2006). With the isolation of stem/ progenitor cells by Hoechst dye exclusion 
being carried out successfully on so many adult stem cell types including mammary, I 
set out to characterise these cells for stem/ progenitor markers and then to confirm their 
identity through tests for self-renewal and mutli-lineage differentiation.   
 
The comparison of the markers expressed on SP and non-SP cells were however, not 
very different. As I screened through the various known mammary stem cell markers 
like CD24, CD29, CD44 and CK5 through flow cytometry, none of them turned out 
markedly different between the SP and non-SP cells. However, the significant 
differential expression of nestin and CK18 does point towards the primitive nature of 
these SP cells.  
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5.6.2.2 Culture of SP Cells 
In order to familiarise myself to the culture system commonly employed for growth of 
MaSC, I started out the culture systems with two positive controls. After having 
successfully cultured spheroid cell clusters from primary neural stem cells as well as 
from a epithelial carcinoma cell line, MCF-7, I went on to attempt single cell cultures of 
the sorted cells into mammospheres, with an aim of proving clonogenicity and self-
renewal. The use of single cell cultures of SP cells from tissues of reduction 
mammoplasties has been reported (Clarke et al., 2005; Dontu et al., 2003a). This 
together with the known anatomy of the mammary tissues and my positive controls 
suggested the feasibility of my experimental plan. 
 
 However, I did not manage to obtain the anticipated results regardless of adjustments in 
terms of growth factors, substrata and even cell densities of the cultures, although I 
confirmed their non-haemopoietic nature through subjecting the SP cells to a semi-solid 
growth assay. The proliferative and clonogenic ability of the SP cells from mammary 
tissues, in contrast with the non-SP cells, has been verified by several groups (Dontu et 
al. 2003a; Clayton et al. 2004; Clarke et al. 2005) and hence, it is likely that the culture 
system is sub-optimal in this case. 
 
In the final results chapter of my thesis, I explored another stem cell marker which has 
been used to isolate different primary and carcinoma cell lines. 















6 Isolation of Stem/ Progenitor Cells in Expressed 
Human Breast Milk by CD133 




While there are several markers that are associated with stemness, many were not 
suitable for use to isolate cells-of-interest as they are intracellular. In terms of cell 
surface markers, CD34 is one of the earlier and more important markers for stem cells, 
particularly of the haemopoietic lineage (Civin et al. 1990). More recently, CD133, an 
antigen 120kDa in size with five transmembrane domain glycoprotein, has also been 
used as both an alternative and/ or in association for haemopoietic stem cells (Yin et al. 
1997; Kobari et al. 2001; Handgretinger et al. 2003). From its primary use as a 
haemopoietic stem cell marker, its expression has since been implicated in the 
identification of neural and endothelial stem cells, and other primitive cells (Piechaczek 
2001). Since it is a primitive cell marker present on haemopoietic and neuro-ectodermal 
stem/ progenitor cells (Yin et al. 1997; Uchida et al. 2000), I hypothesise that putative 
HBM epithelial stem cells may express CD133, allowing their prospective isolation. 
Hence in this chapter, I sought to isolate viable cells-of-interest by means of CD133 
which could potentially be primitive stem cells to carry out more characterisation, in 
particular pertaining to self-renewal and clonogenicity. 
 
6.2 Isolation of Cells-of-interest using CD133-tagged 
DynabeadsTM 
6.2.1 Occurrence of CD133+ Cells 
Incubation of WCP in HBM with CD133-tagged DynabeadsTM revealed a small but 
distinct population of cells accounting for less than 1% of the total cell population 
(Figure 6-1). This was confirmed by direct immunostaining for CD133 (Figure 6-2).  




Figure 6-1 Isolation of CD133-positive cells. CD133-tagged DynabeadsTM observed 






Figure 6-2 Immunocytochemical staining of CD133-positive cells. Cells isolated 
with CD133-tagged DynabeadsTM, positively-immunostained for CD133 (blue from 
Vector blue staining) (a) or stained with H & E (b). Erythrocytes were used as external 
negative control in this instance which were not stained (c). 
 
 
6.2.2 Growth Kinetics 
I tried culturing the cells right after isolation in a 96-well plate but was unsuccessful. 
Numerous DynabeadsTM remain bound on the positive cells, despite prolonged 
incubation time with the DNase and the magnetic column. DynabeadsTM isolated 
CD133+ cells were cultured in epithelial cell culture media for two weeks (n=5) but did 
not result in any proliferation. DynabeadsTM were seen to be bound to the cells despite 
culturing the cells beyond a week. Reports have established a detrimental effect of 
attached DynabeadsTM on cell proliferation and metabolism (Tiwari et al. 2003). Hence, 
Chapter 6. Isolation of Stem/ Progenitor Cells in Expressed HBM by CD133 
 
 136 
using DynabeadsTM isolated cells may be helpful for identifying and characterising cell 
types, but not in experimental set-ups where cells are subjected to culture.  
 
6.2.3 Control Study with CD45-tagged DynabeadsTM 
I hence decided to attempt CD45 isolation of the immune cells from HBM  to ascertain 
the reliability of this technique for isolation of cells. CD45-tagged DynabeadsTM was 
not able to deplete the HBM of leukocytes, leaving a large majority of CD45-positive 





Figure 6-3 CD45-tagged DynabeadsTM isolation of cells from HBM. The negative 
fraction of the isolation (a-b) was found to still contain a lot of CD45+ lymphocytes (b 
stained with H&E). The positive fraction (c) hardly had any cells (arrows), some of 




The isolation of CD45+ cells, which comprises up to 90% of cells in HBM was of 
extremely low efficiency. MaSC derived from tissue occur at a frequency of 4 in 1000, 
based on the self-renewal property exhibited through mammosphere formation (Dontu 
et al. 2003a). It is expected that the frequency of MaSC in HBM would be several log 
Chapter 6. Isolation of Stem/ Progenitor Cells in Expressed HBM by CD133 
 
 137 
folds lower than this. Such low proportion of cells-of-interest increases the unreliability 
of this method for optimal isolation, questioning the purity of cells isolated. Moreover, 
the continued attachment of CD133 tagged-DynabeadsTM to the putative stem cells over 
seven days would have impeded the ability of these cells to proliferate or function. A 
more efficient system using fluorescent-tagged antibody may overcome these problems.  
 
 
6.3 Isolation of Cells-of-interest using CD133 Antibody Tagged 
with Fluorescence 
 
6.3.1 Occurrence of CD133+ Cells 
Using RPE-tagged CD133 antibody from Miltenyi, I found that 2.0±0.003% (n=23) of 
the cellular component in HBM are CD133+ (Figure 6-4), which was unaffected by 
either the maternal age or the duration of breastfeeding (Figure 6-5).  
 
 
Figure 6-4 CD133 Sorting by FACS.  Flow cytometry of CD133 staining on cellular 
component of HBM (a), as compared to the isotype control (b).  




Figure 6-5 Correlation Analysis of CD133+ Cells. There were no relationship 
between the frequency of CD133 cells and the duration of breastfeeding (a), nor the age 
of the mother (b).  
 
6.3.2 Characterisation of CD133+ Cells 
CD133-positive HBM cells did not demonstrate any significant differences in their 
expression of EPCAM, CD34, CD45, lineage and CD105 with CD133-negative HBM 
cells (Table 6-1). This indicated that sorting through the surface marker, CD133, 
enriched for neither the mammary epithelial cells nor cells of the non-epithelial lineage. 
 
 
Table 6-1: Antigens expressed on CD133+ and CD133- cells in HBM. 
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6.3.3 Mammosphere Culture of CD133+ Cells 
Both CD133-positive and CD133-negative HBM cells did not generate any 
mammospheres in serum-free growth conditions.  
 
 
6.3.4 Methylcellulose Culture of CD133+ Cells 
6.3.4.1 Positive Control 
As an appropriate control, I sorted the WCP from umbilical cord blood for Hoechst dye 
exclusion and then plated the sorted CD133-positive cells into the same methylcellulose 
system. CD133-positive fraction of umbilical cord blood demonstrated multi-lineage 
haemopoietic colony forming capacity after two weeks, validating our sorting protocol 
as well as methylcellulose culture system (Figure 6-6).  
 
 
Figure 6-6 Methylcellulose Culture of CD133+ Cells from Cord Blood. CD133+ 
cells from cord blood formed multi-lineage colonies on CFU assays. Magnification of 
4X. 
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6.3.4.2 In Vitro Expansion  
As the CD133 fraction in bone marrow and cord blood is enriched for haemopoietic 
stem cells (Charrier et al. 2002; Yao et al. 2006; Lu et al. 2007), I investigated CD133-
positive cells in HBM for the presence of haemopoietic stem cell types in the same 
methylcellulose culture system mentioned earlier in Section 5.5. Similar to the SP and 
non-SP fractions of HBM, I did not find the expansion of any haemopoietic colonies 




6.4.1 Summary of Results 
In this chapter, I found no more than 2% of CD133-positive cells in HBM, a 
phenomenon never described nor published before. Two methods, namely the use of 
DynabeadsTM and flow sorting with fluorescent-tagged CD133 antibody were employed 
with the latter found to pull out a population of CD133-positive cells which was more 
suitable for culture purposes. 
 
With regards to the characterisation by flow cytometry, there was no significant 
difference between the CD133-positive and CD133-negative cells (p-value > 0.05). 
This is perplexing as the difference turned out more insignificant compared to the 
difference between SP and non-SP cells. 
 
I subjected the CD133-positive and CD133-negative cells to methylcellulose as well as 
mammosphere culture system and both, similar to the SP cells did not have any colonies 
or mammospheres forming respectively.  
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6.4.2 Critical Assessment 
6.4.2.1 Isolation of CD133+ Cells 
Initially, I made use of CD133-tagged DynabeadsTM to selectively pull out the potential 
stem/ progenitor cells. Upon problems of high cell loss (positive cells being still present 
in the negative fraction) and the large DynabeadsTM still attached onto the sorted cells, I 
believe it would be fruitful to use the same method of CD133 isolation but with a 
different kit. FACS was then employed for its high reliability and efficiency. Therefore, 
I planned to carry out isolation of CD133-positive cells using fluorescent-tagged CD133 




6.4.2.2 Characterisation of CD133+ Cells 
CD133-positive cells in HBM are completely novel. It has been reported on mammary 
tumours (Wright et al. 2008) raising the question of link between the cells found in 
HBM and the tumorigenesis of mammary cells, resulting in malignancies.  
Hypothetically, these cells in HBM could serve as a potential source for research groups 
to study the transformation of mammary cells and the changes involved, which in the 
long run could bring about the better understanding and possibly even novel therapies 
for mammary cancers. 
 
The simple characterisation of these cells for EPCAM and other non-epithelial cell 
markers however did not provide further clues to their identity as from the flow 
cytometry results, there appear no difference between the CD133-positive and CD133-
negative cells. I therefore went ahead with the mammosphere and methylcellulose 
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culture so that I can conclude if there are mammary and/ or haemopoietic stem/ 
progenitor cells in either population. With the negative culture results and a positive 
control that validate my sorting and culture protocol, I can certainly conclude the 
absence of mammary and haemopoietic stem/ progenitor cells in HBM within my 
culture parameters. 













7 General Discussion 




The search and use of stem cells in the human has been under the spotlight particularly 
in recent years. Sources for haemopoietic stem/ progenitor cells are plentiful and many 
of which are already in use for clinical transplantation, proving their functionality and 
widespread potential. However, demand still far exceeds supply and hence, we still 
have many research groups around the world working on the in vitro expansion of these 
cells and coming up with novel sources like  making of artificial blood  to circumvent 
the shortage problem. HBM has previously been shown to contain a large amount of 
haemopoietic cell types, but it has never been explored as a source of HSC.  
 
MaSC are also under stringent scrutiny in recent years, due in no small part to the fact 
that breast cancer is the most common cancer among females worldwide and that MaSC 
have been implicated in the progress of this prevalent disease  (Dontu et al. 2003b; 
Dontu et al. 2005; Ponti et al. 2005). While MaSC have been obtained from mammary 
tissues, this involves an invasive procedure which limits its accessibility. Based on 
studies which have proved that stem cells are discharged into luminal cavities, in the 
case of mesenchymal progenitor cells in menstrual blood and epithelial, urothelial and 
smooth muscle lineage stem/ progenitor cells in urine (Hida et al. 2008; Musina et al. 
2008; Zhang et al. 2008), I proposed the question of MaSC being present in HBM, 
which is the main aim of my study. As a side question, I also decided to investigate 
HSC, given that the main cellular component of HBM is immune cells, responsible for 
much of the beneficial effects conferred to the baby. 
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In my study, I aimed to isolate MaSC and HSC from HBM, believing that with 
successful derivation of these cells from HBM, it will aid progress of research in these 
two fields and provide a novel and non-invasive source of mammary and/ or 
haemopoietic stem/ progenitor cells. In addition, this would allow a more detailed and 
complete understanding of the various components of HBM, possibly even unravelling 
more unknowns about HBM. 
 
7.2 Hypotheses 
The aim of this project was to determine whether there are any adult stem/ progenitor 
cells present in HBM and that if they are present, whether they are able to differentiate 
down various epithelial and/ or haemopoietic lineages, demonstrating multipotency. 
This would potentially have implications for breast tissue engineering, clinical 
application for haemopoietic cell use and for elucidation of the mechanisms between 
MaSC and progression to malignancy as well as the mechanism of lactogenesis. In 
Section 1.5.1, I have hypothesised that adult stem/ progenitor cells are present in HBM 
and that they are able to differentiate down various lineages and perhaps even 
transdifferentiate. Here, I set off answering my questions by (i) searching for markers of 
various lineages, (ii) culturing the adherent cells to get a purer population of cells to 
work with in search of my cells-of-interest and lastly, (iii) the use of specific markers in 
an attempt to isolate the cells of my interest. 
 
 




7.3.1 Cellular Component of Expressed Human Breast Milk 
I have discovered the presence of cell surface markers that have never been reported in 
the cellular component of HBM. The presence of these markers suggests the presence 
of one or more novel cell types in HBM.  Specifically, there was positive staining of 
stem/ progenitor markers of various lineages like ABCG2, CD24, β-1 and α-6 integrins, 
all of which have been implicated in the identification of MaSC (Shackleton et al. 2006; 
Stingl et al. 2006a, b). 
 
The presence of  a  large number of IFs were investigated with flow cytometry and the 
positive expression of CK5 and the neural IFs once again suggests the presence of a yet 
still uncharacterised cell population in HBM. 
 
 
7.3.2 In Vitro Expansion of Adherent Cells in Selective Medium 
I have managed to circumvent the problem of staining WCP in HBM by expanding the 
adherent cells for up to 30 days. These cells were identified as epithelial cells by 
epithelial specific immunocytochemistry. From their growth kinetics, it is apparent that 
they demonstrate great variability in doubling time and rate of proliferation.  
 
In chapter 3, I have observed the presence of CK5 RNA expression in WCP of HBM. 
However, in chapter 4, when I directly compared the expression level of CK5 and 
CK14 by means of RT-PCR, it was relatively much lower, so much so that they are 
beneath the threshold level of positivity. In the case of cultured cells, I observed nestin 
and CK5 positivity and a co-localisation of the 2 IFs in 11.4±4.2% of cells. The pattern 
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of staining seems to suggest the presence of a hierarchy of cells within the lobulo-
alveoli structure which are being sloughed off into HBM with the nestin-positive cells 
being the multipotent progenitor cells that differentiate to express CK5 as the mammary 
stem/ progenitor cells which further differentiate into the known luminal epithelial, 
myoepithelial and ductal cells. 
 
7.3.3 Attempts to Isolate the Stem/ Progenitor Cells 
7.3.3.1 Hoechst Dye Exclusion 
The method of Hoechst dye exclusion is a method employed by many stem cell groups 
to isolate a side-population of cells which possess stem cell properties like self-renewal, 
clonogenicity and the ability to differentiate into mature cell types.  In HBM, I found a 
proportion of approximately 2.1% of cells forming the side-population. The proportion 
of side-population appears to be unaffected by the duration of breastfeeding. SP was 
highly nestin-positive and not CK18, suggestive of their primitive identity. Further to 
this, flow cytometry exploring the differences between SP and non-SP for a series of 
other markers indicative of MaSC, mammary epithelial cells as well as non-epithelial 
cells concluded minimal difference with exception of EPCAM and CD31. 
 
With appropriate controls in place, it was found that neither SP nor non-SP cellular 
fraction contain mammary or haemopoietic stem/ progenitor cells that could be cultured. 
It might be due to the insufficiencies of the medium, although I have proven that 
addition of EGF, bFGF, FBS or conditioned medium does not improve the culture 
conditions for mammary or haemopoietic stem/ progenitor cells in this setting. There 
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I attempted the isolation of CD133-positive cells through two different means before 
finalising the use of fluorescence-tagged antibodies, which was preferred due to the 
pure selection, higher efficiency of sorting and suitability for culture. 
 
Comparable to SP cells, I found a proportion of 2.0% of cells that are CD133-positive 
and this proportion is unaffected by both the maternal age and the duration of 
breastfeeding. While CD133 and SP picked up the same proportion of cells, it is 
noteworthy to mention that they are unlikely to be the same cells as I have done a 
comparison of the SP and non-SP for expression of CD133, which I found to be 6.1±1.9 
and 3.9±2.0% (Table 5-1, page 116). Characterisation of CD133-positive and CD133-
negative cells to discover any differences in the other cell surface markers they possess, 
namely EPCAM, CD45, Lin, CD105 and CD34, did not show any significant difference. 
 
 Neither CD133-positive and CD133-negative cells generated mammospheres or 
colonies in the mammospheres and methylcellulose cultures, once again concluding that 








This project proved to be more challenging than initially envisioned. Along the way of 
answering the hypotheses, several other factors limiting further research are detailed as 
follows. 
 
Where the recruitment of participants was concerned, I had intended to recruit from just 
one institution. But in the first year, I faced great challenges in liasing with potential 
volunteers in the first few days postpartum when their milk supply has yet to be 
established and I had difficulties getting them enrolled. In addition, there were issues 
with the volume of HBM that they are comfortable with donating. I first started out with 
a mere 10 to 15mL per donor which yielded a hardly visible cell pellet to work with. In 
the following year, I managed to get increased donations from lactating women through 
the various breastfeeding support groups, in particular the Singapore Motherhood 
Forum. Through these support groups, I managed to involve a larger number of women 
who individually are able to contribute larger volumes of HBM. 
 
In attempting to characterise the cellular component of HBM, the high background 
staining of uncultured cells proved challenging. Despite optimising the staining protocol 
with increased incubation with blocking agent, by altering the components of the 
blocking agent and adjusting the incubation times with antibodies and even antibodies 
against same antigens purchased from different companies, a high background staining 
still existed. I moved to show the presence of the various lineage markers through RT-
PCR and flow cytometry which allows the right gating of single cells as well as rapid 
analysis of at least 20,000 single cells within a short period of time. 
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In the search for an appropriate means to isolate my cells-of-interest, a major limitation 
was the lack of suitable markers. Even if the cells-of-interest were to be MaSC, the 
markers to identify them were not definitive.  The most definitive work on MaSC was 
in my opinion that of Shackleton and team where they managed to generate a functional 
mammary gland from a single mammary stem cell based on the marker of Lin-
CD29hiCD24+ (Shackleton et al. 2006). However, the same markers are also used for 
identifying white adipocyte progenitors in vivo (Rodeheffer et al. 2008). CK5 has also 
been named as a mammary stem cell marker (Bocker et al. 2002; Dontu et al. 2003a) 
but it has also been implicated in the identification of epitheloid mesothelioma (Clover 
et al. 1997) and epidermis (Mischke and Wild 1987). 
 
Finally, with the negative results I got in the culture components after sorting, the 
controls in place had to be extremely exhaustive ranging from fetal tissue to umbilical 
cord blood to cell lines which each had its own difficulty in terms of availability. 
Nonetheless, it was a great chance to work with a wide variety of tissues, an opportunity 
not many researchers get, since such tissues are scarce and not usually available. 
 
Although not entirely exhaustive, but certainly within the confines and limitations of 
my graduate study, an in vivo experimental system may be a better approach in 
identifying putative stem cells, if they are present, as evidently the in vitro conditions 
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7.5 Implications of This Research 
The significance of a positive result for this work is profound as mentioned in Section 
1.5.2. Besides providing novel cell sources for breast tissue engineering and potential 
banking of stem cells from all lactating females, a positive result would enable deeper 
understanding of the synergistic relationship breastfeeding has on the mother and infant. 
MaSC from HBM could aid to elucidate mechanisms that brings about mutagenesis and 
oncogenesis, which breastfeeding has been shown to exert a protective effect (Byers et 
al. 1985; Katsouyanni et al. 1986; Newcomb et al. 1994; Brinton et al. 1995).  
 
 
In addition, it is well studied that fetal cells have been found in maternal blood and 
organs up to 30 years after birth (O'Donoghue et al. 2004; Tan et al. 2005; O'Donoghue 
et al. 2008) but less is known of the reverse whereby maternal cells cross the placenta 
and implant in perinatal tissues. If HBM contains stem or pluripotent cells, do these 
cells implant in the infant and are the transportation of these maternal stem cells to the 
breastfeeding infant associated with possible benefits (increased population of 
progenitors that assist with repair of damaged tissues) or deleterious effects to the infant 
by causing graft versus host reactions, autoimmune processes or stem cell derived 
neoplasia? Afterall, it has already been shown in various models that leukocytes from 
milk escape digestion in the infant’s gut and enter the circulation of the infant (Weiler et 
al. 1983; Slade and Schwartz 1987; Jain et al. 1989; Arvola et al. 2000).  
 
 
With my results, we can conclude that while there are indeed promising markers, cells 
isolated with these markers were not capable of proliferating in vitro within my 
experimental parameters. This can be explained with the fact that my culture conditions, 
although optimised with a variety of growth factors and substrata remains sub-optimal. 
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The second explanation would be that stem/ progenitor cells though present in the 
mammary gland are not passed out into HBM. With respect to the latter scenario, there 
are certainly specific mechanisms within the human which prevents the sloughing of 
such important cells of our system. Instead, perhaps only cells that are meant to be 
replaced or meant for the baby’s immune system are sloughed off into HBM. Clearly, 
mammary and haemopoietic stem/ progenitor cells are not in the list. 
 
With my results, we have answered one important biological question asked not just by 
us and it will perhaps, conclude the search for these much-sought after cells in HBM, 
which was intitally viewed by us and others as a potential novel non-invasive source of 
such cells (McGregor and Rogo 2006; Cregan et al. 2007). 
 
 
7.6 Directions for Future Research 
7.6.1 Isolation of Cells-of-interest 
 
As mentioned earlier, Shackleton and team demonstrated that cells from reduction 
mammoplasties contained within the Lin-CD29hiCD24low population are able to 
reconstitute an entire functional mammary gland (Shackleton et al. 2006) and that this is, 
by far, demonstration at the highest level of what would constitute a true stem cell, at 
least in the murine model. CD29 and CD24 have been reported to be present on MaSC 
in both mouse and human (Shackleton et al. 2006; Stingl et al. 2006b). Therefore, it 
might be worthwhile to triple select for Lin-CD29hiCD24low cells and attempt a 
mammosphere culture. Removal of haemopoietic lineages from WCP from HBM 
(Rossette-separation, StemCells) by magnetic sorting can be pursued, following which, 
flow-cytometric sorting of CD29+ and CD24+ cells by dual-colour sorting can be 
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carried out. As was done with the cells isolated by the other methods, these cells can be 
characterised and put into cultures to find out their proliferative ability, clonogenicity 
and ability to self-renew. 
 
7.6.2 In Vivo Work 
To prove with absolute certainty, one should transplant these cells from HBM into 
fatpad removed nonobese diabetes/severe combined immunodeficiency mice. To do this, 
one would also be required to optimise the cell numbers to be transplanted and the 




During the course of my studies for this thesis, I have established, for the first time, the 
presence of stem cell markers like nestin, CD133, and the presence of SP cells in 
expressed HBM. Contrary to my hypothesis, cells expressing these markers, which are 
often considered characteristic of stem/ progenitor cells, could not be cultured using the 
standard stem cell culture techniques I have employed. Although not exhaustive, the 
culture methods I have used were all I could perform within the confines and limitations 
of my graduate studies. An in vivo experimental system may therefore be necessary to 
identify the putative stem cells, if indeed they are present, as I have proved that standard 
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